Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:pyridine nucleotide
go back to main search page
Accession:CHEBI:36980 term browser browse the term
Synonyms:related_synonym: pyridine nucleotides


show annotations for term's descendants           Sort by:
NAD zwitterion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACMSD aminocarboxymuconate semialdehyde decarboxylase increases abundance ISO ACMSD protein results in increased abundance of NAD CTD PMID:17896587 NCBI chr 2:134,838,616...134,902,034
Ensembl chr 2:134,838,616...134,902,034 		JBrowse link
G AKR1A1 aldo-keto reductase family 1 member A1 multiple interactions EXP NAD promotes the reaction [AKR1A1 protein affects the chemical synthesis of benzo(a)pyrene-7,8-dione]; NAD promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 NCBI chr 1:45,550,826...45,570,049
Ensembl chr 1:45,550,543...45,570,049 		JBrowse link
G AKR1C1 aldo-keto reductase family 1 member C1 multiple interactions EXP [AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr10:4,963,415...4,983,283
Ensembl chr10:4,963,253...4,983,283 		JBrowse link
G AKR1C2 aldo-keto reductase family 1 member C2 multiple interactions EXP [AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr10:4,987,775...5,018,000
Ensembl chr10:4,987,775...5,018,031 		JBrowse link
G AKR1C3 aldo-keto reductase family 1 member C3 multiple interactions EXP [AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr10:5,048,781...5,107,686
Ensembl chr10:5,035,354...5,107,686 		JBrowse link
G AKT1 AKT serine/threonine kinase 1 multiple interactions EXP 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein] CTD PMID:25536389 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751 		JBrowse link
G ALDH1A1 aldehyde dehydrogenase 1 family member A1 multiple interactions
increases activity		 EXP
ISO		 [ALDH1A1 protein binds to NAD] which results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; [NAD co-treated with propionaldehyde] inhibits the reaction [Acrolein results in decreased activity of ALDH1A1 protein]; ALDH1A1 protein binds to and results in increased reduction of NAD; NAD binds to and results in increased activity of ALDH1A1 protein; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH1A1 protein]
NAD results in increased activity of ALDH1A1 protein		 CTD PMID:10559215 PMID:10856427 PMID:21256123 PMID:22339434 PMID:25450233 NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442 		JBrowse link
G ALDH1B1 aldehyde dehydrogenase 1 family member B1 multiple interactions EXP [ALDH1B1 protein co-treated with NAD] results in increased metabolism of Acetaldehyde; [ALDH1B1 protein co-treated with NAD] results in increased metabolism of propionaldehyde CTD PMID:7779080 NCBI chr 9:38,392,702...38,398,661
Ensembl chr 9:38,392,702...38,398,661 		JBrowse link
G ALDH2 aldehyde dehydrogenase 2 family member multiple interactions
affects binding
affects abundance		 EXP
ISO		 [ALDH2 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; NAD inhibits the reaction [[Ethanol co-treated with Lead] results in decreased expression of and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Ethanol results in decreased expression of and results in decreased activity of ALDH2 protein]
ALDH2 protein binds to NAD
NAD binds to ALDH2 protein
Magnesium affects the reaction [NAD binds to ALDH2 protein]
ALDH2 gene polymorphism affects the abundance of NAD; ALDH2 protein affects the abundance of NAD		 CTD PMID:10559215 PMID:15629893 PMID:15900217 PMID:21276780 PMID:22339434 More... NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532 		JBrowse link
G ALDH3A1 aldehyde dehydrogenase 3 family member A1 multiple interactions
increases activity		 EXP
ISO		 [ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde
NAD results in increased activity of ALDH3A1 protein		 CTD PMID:10856427 PMID:21256123 NCBI chr17:19,737,984...19,748,298
Ensembl chr17:19,737,984...19,748,943 		JBrowse link
G ALDH5A1 aldehyde dehydrogenase 5 family member A1 multiple interactions ISO NAD binds to and affects the activity of ALDH5A1 protein CTD PMID:18926807 NCBI chr 6:24,494,969...24,537,207
Ensembl chr 6:24,494,867...24,537,207 		JBrowse link
G BAX BCL2 associated X, apoptosis regulator decreases expression EXP NAD results in decreased expression of BAX protein CTD PMID:12390773 NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798 		JBrowse link
G BCL2 BCL2 apoptosis regulator increases expression EXP NAD results in increased expression of BCL2 protein CTD PMID:12390773 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128 		JBrowse link
G BCL2L1 BCL2 like 1 multiple interactions ISO NAD inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] CTD PMID:11461765 NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989 		JBrowse link
G BDH1 3-hydroxybutyrate dehydrogenase 1 multiple interactions EXP NAD binds to and results in increased activity of BDH1 protein CTD PMID:25526675 NCBI chr 3:197,509,783...197,573,343
Ensembl chr 3:197,509,783...197,573,323 		JBrowse link
G BDH2 3-hydroxybutyrate dehydrogenase 2 multiple interactions EXP NAD binds to and results in increased activity of BDH2 protein CTD PMID:25526675 NCBI chr 4:103,077,592...103,099,834
Ensembl chr 4:103,077,592...103,099,870 		JBrowse link
G BMAL1 basic helix-loop-helix ARNT like 1 decreases oxidation ISO BMAL1 gene mutant form results in decreased oxidation of NAD CTD PMID:27056296 NCBI chr11:13,276,652...13,387,266
Ensembl chr11:13,276,652...13,387,266 		JBrowse link
G CASP3 caspase 3 multiple interactions ISO NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; NAD inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; NAD inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] CTD PMID:24040102 PMID:24491677 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062 		JBrowse link
G CAT catalase multiple interactions EXP CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] CTD PMID:10334203 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CBR4 carbonyl reductase 4 multiple interactions EXP NAD binds to and results in increased activity of CBR4 protein CTD PMID:25526675 NCBI chr 4:168,894,486...169,010,255
Ensembl chr 4:168,863,770...169,010,275 		JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A multiple interactions ISO NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] CTD PMID:22561310 NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337 		JBrowse link
G CDKN1B cyclin dependent kinase inhibitor 1B multiple interactions ISO NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] CTD PMID:22561310 NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369 		JBrowse link
G CHRNA9 cholinergic receptor nicotinic alpha 9 subunit multiple interactions EXP CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 4:40,335,333...40,355,217
Ensembl chr 4:40,335,333...40,355,217 		JBrowse link
G CSF2 colony stimulating factor 2 multiple interactions ISO [NAD results in increased abundance of Reactive Oxygen Species] which results in increased expression of CSF2 protein CTD PMID:11752025 NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170 		JBrowse link
G CYB5B cytochrome b5 type B multiple interactions EXP [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr16:69,424,619...69,466,264
Ensembl chr16:69,398,402...69,466,264 		JBrowse link
G CYB5R3 cytochrome b5 reductase 3 affects binding
multiple interactions		 EXP CYB5R3 protein binds to NAD
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine		 CTD PMID:16469290 PMID:25170804 NCBI chr22:42,617,840...42,649,392
Ensembl chr22:42,615,730...42,720,870 		JBrowse link
G DCXR dicarbonyl and L-xylulose reductase multiple interactions EXP 1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased reduction of Diacetyl; [DCXR protein co-treated with NAD] results in increased reduction of Xylulose; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin] CTD PMID:28595002 NCBI chr17:82,035,858...82,037,697
Ensembl chr17:82,035,136...82,037,709 		JBrowse link
G DEK DEK proto-oncogene increases oxidation EXP DEK protein results in increased oxidation of NAD CTD PMID:28558019 NCBI chr 6:18,223,860...18,264,530
Ensembl chr 6:18,223,860...18,264,548 		JBrowse link
G DHRS9 dehydrogenase/reductase 9 multiple interactions EXP NAD binds to and results in increased activity of DHRS9 protein CTD PMID:25526675 NCBI chr 2:169,067,077...169,096,167
Ensembl chr 2:169,064,789...169,096,167 		JBrowse link
G ENOX2 ecto-NOX disulfide-thiol exchanger 2 multiple interactions EXP [epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD; [phenoxodiol results in decreased activity of ENOX2 protein] which results in increased abundance of NAD CTD PMID:20518072 NCBI chr  X:130,622,325...130,903,209
Ensembl chr  X:130,622,325...130,903,234 		JBrowse link
G ERCC6 ERCC excision repair 6, chromatin remodeling factor multiple interactions
decreases abundance
increases ADP-ribosylation
increases metabolic processing		 EXP
ISO		 ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased abundance of NAD]; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]
nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD]
NAD results in increased ADP-ribosylation of ERCC6 protein
ERCC6 gene mutant form results in increased metabolism of NAD		 CTD PMID:25440059 NCBI chr10:49,434,881...49,539,538
Ensembl chr10:49,454,168...49,539,538 		JBrowse link
G GALE UDP-galactose-4-epimerase multiple interactions EXP NAD binds to and results in increased activity of GALE protein CTD PMID:25526675 NCBI chr 1:23,795,599...23,800,754
Ensembl chr 1:23,795,599...23,800,781 		JBrowse link
G GALNT1 polypeptide N-acetylgalactosaminyltransferase 1 increases expression EXP NAD results in increased expression of GALNT1 mRNA CTD PMID:29935245 NCBI chr18:35,580,922...35,711,834
Ensembl chr18:35,581,117...35,711,834 		JBrowse link
G GAPDH glyceraldehyde-3-phosphate dehydrogenase multiple interactions EXP
ISO		 [GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]		 CTD PMID:15788719 NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374 		JBrowse link
G GLB1 galactosidase beta 1 multiple interactions ISO NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] CTD PMID:22561310 NCBI chr 3:32,961,108...33,097,146
Ensembl chr 3:32,996,609...33,097,202 		JBrowse link
G GSK3B glycogen synthase kinase 3 beta increases abundance
multiple interactions		 EXP GSK3B protein mutant form results in increased abundance of NAD metabolite
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]		 CTD PMID:25246272 PMID:25536389 NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994 		JBrowse link
G GSR glutathione-disulfide reductase multiple interactions ISO NAD inhibits the reaction [Doxorubicin results in decreased activity of GSR protein] CTD PMID:24491677 NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846 		JBrowse link
G HADH hydroxyacyl-CoA dehydrogenase increases metabolic processing EXP HADH protein results in increased metabolism of NAD CTD PMID:10600649 NCBI chr 4:107,989,889...108,035,171
Ensembl chr 4:107,989,714...108,035,241 		JBrowse link
G HPGD 15-hydroxyprostaglandin dehydrogenase multiple interactions EXP [Celecoxib co-treated with NAD] binds to HPGD protein; [Diclofenac co-treated with NAD] binds to HPGD protein; [Dinoprostone co-treated with NAD] binds to HPGD protein; [Fenoprofen co-treated with NAD] binds to HPGD protein; [Indomethacin co-treated with NAD] binds to HPGD protein; [Ketoprofen co-treated with NAD] binds to HPGD protein; [Niflumic Acid co-treated with NAD] binds to HPGD protein; [Pioglitazone co-treated with NAD] binds to HPGD protein; [Rosiglitazone co-treated with NAD] binds to HPGD protein; NAD binds to and results in increased activity of HPGD protein CTD PMID:25526675 NCBI chr 4:174,490,175...174,522,893
Ensembl chr 4:174,490,175...174,523,154 		JBrowse link
G HPSE heparanase increases expression ISO NAD results in increased expression of HPSE mRNA; NAD results in increased expression of HPSE protein CTD PMID:19429930 NCBI chr 4:83,292,461...83,335,153
Ensembl chr 4:83,292,461...83,335,153 		JBrowse link
G HRAS HRas proto-oncogene, GTPase multiple interactions EXP [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene] CTD PMID:10334203 NCBI chr11:532,242...535,576
Ensembl chr11:532,242...537,321 		JBrowse link
G HSD11B1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions EXP [Androstane-3,17-diol co-treated with NAD] binds to HSD11B1 protein; [Disulfiram co-treated with NAD] binds to HSD11B1 protein; [Estradiol co-treated with NAD] binds to HSD11B1 protein; [Quercetin co-treated with NAD] binds to HSD11B1 protein; [Testosterone co-treated with NAD] binds to HSD11B1 protein CTD PMID:25526675 NCBI chr 1:209,686,179...209,734,929
Ensembl chr 1:209,686,178...209,734,949 		JBrowse link
G HSD11B2 hydroxysteroid 11-beta dehydrogenase 2 increases reduction
multiple interactions		 ISO
EXP		 HSD11B2 protein results in increased reduction of NAD
Ziram inhibits the reaction [HSD11B2 protein results in increased reduction of NAD]		 CTD PMID:26859423 NCBI chr16:67,429,801...67,437,553
Ensembl chr16:67,430,652...67,437,553 		JBrowse link
G HSD17B10 hydroxysteroid 17-beta dehydrogenase 10 multiple interactions EXP [20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein; [Androstane-3,17-diol co-treated with NAD] binds to HSD17B10 protein; [cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein; [Cholestanol co-treated with NAD] binds to HSD17B10 protein; [Pregnanolone co-treated with NAD] binds to HSD17B10 protein; [Progesterone co-treated with NAD] binds to HSD17B10 protein; NAD binds to and results in increased activity of HSD17B10 protein CTD PMID:25526675 NCBI chr  X:53,431,258...53,434,376
Ensembl chr  X:53,431,258...53,434,370 		JBrowse link
G HSD17B11 hydroxysteroid 17-beta dehydrogenase 11 multiple interactions EXP NAD binds to and results in increased activity of HSD17B11 protein CTD PMID:25526675 NCBI chr 4:87,336,515...87,391,188
Ensembl chr 4:87,336,515...87,391,188 		JBrowse link
G HSD17B13 hydroxysteroid 17-beta dehydrogenase 13 multiple interactions EXP NAD binds to and results in increased activity of HSD17B13 protein CTD PMID:25526675 NCBI chr 4:87,303,794...87,322,882
Ensembl chr 4:87,303,789...87,322,886 		JBrowse link
G HSD17B14 hydroxysteroid 17-beta dehydrogenase 14 multiple interactions EXP NAD binds to and results in increased activity of HSD17B14 protein CTD PMID:25526675 NCBI chr19:48,813,018...48,836,491
Ensembl chr19:48,813,018...48,836,510 		JBrowse link
G HSD17B2 hydroxysteroid 17-beta dehydrogenase 2 multiple interactions EXP NAD binds to and results in increased activity of HSD17B2 protein CTD PMID:25526675 NCBI chr16:82,035,253...82,098,534
Ensembl chr16:82,035,004...82,098,534 		JBrowse link
G HSD17B4 hydroxysteroid 17-beta dehydrogenase 4 multiple interactions EXP NAD binds to and results in increased activity of HSD17B4 protein CTD PMID:25526675 NCBI chr 5:119,452,497...119,542,332
Ensembl chr 5:119,452,465...119,637,199 		JBrowse link
G HSD17B6 hydroxysteroid 17-beta dehydrogenase 6 multiple interactions EXP NAD binds to and results in increased activity of HSD17B6 protein CTD PMID:25526675 NCBI chr12:56,763,324...56,787,790
Ensembl chr12:56,752,161...56,787,790 		JBrowse link
G HSD17B8 hydroxysteroid 17-beta dehydrogenase 8 multiple interactions EXP [Gossypol co-treated with NAD] binds to HSD17B8 protein CTD PMID:25526675 NCBI chr 6:33,204,655...33,206,831
Ensembl chr 6:33,204,655...33,206,831 		JBrowse link
G HSD3B1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions EXP NAD binds to and results in increased activity of HSD3B1 protein CTD PMID:25526675 NCBI chr 1:119,507,203...119,515,058
Ensembl chr 1:119,507,198...119,515,054 		JBrowse link
G HSD3B2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 multiple interactions EXP NAD binds to and results in increased activity of HSD3B2 protein CTD PMID:25526675 NCBI chr 1:119,414,931...119,423,034
Ensembl chr 1:119,414,931...119,423,035 		JBrowse link
G HSD3B7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions EXP NAD binds to and results in increased activity of HSD3B7 protein CTD PMID:25526675 NCBI chr16:30,985,207...30,989,147
Ensembl chr16:30,985,207...30,989,147 		JBrowse link
G IDH2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance		 ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD metabolite]; Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD]
IDH2 protein mutant form results in increased abundance of NAD; IDH2 protein mutant form results in increased abundance of NAD metabolite		 CTD PMID:27469509 NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,477 		JBrowse link
G IGFBP1 insulin like growth factor binding protein 1 multiple interactions
increases expression		 EXP NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]
NAD results in increased expression of IGFBP1 mRNA		 CTD PMID:32781018 NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660 		JBrowse link
G IL1B interleukin 1 beta multiple interactions EXP 2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G INSR insulin receptor multiple interactions EXP 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein] CTD PMID:25536389 NCBI chr19:7,112,265...7,294,414
Ensembl chr19:7,112,255...7,294,414 		JBrowse link
G LDHA lactate dehydrogenase A increases oxidation ISO LDHA protein results in increased oxidation of NAD CTD PMID:8632003 NCBI chr11:18,394,563...18,408,425
Ensembl chr11:18,394,560...18,408,425 		JBrowse link
G MIR34A microRNA 34a multiple interactions
decreases abundance		 ISO [[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD] CTD PMID:23834033 NCBI chr 1:9,151,668...9,151,777
Ensembl chr 1:9,151,668...9,151,777 		JBrowse link
G MTARC1 mitochondrial amidoxime reducing component 1 multiple interactions EXP [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine] CTD PMID:25170804 PMID:29856598 NCBI chr 1:220,786,913...220,819,659
Ensembl chr 1:220,786,352...220,819,659 		JBrowse link
G MTARC2 mitochondrial amidoxime reducing component 2 multiple interactions EXP [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr 1:220,748,322...220,784,815
Ensembl chr 1:220,748,225...220,784,815 		JBrowse link
G MUC2 mucin 2, oligomeric mucus/gel-forming increases expression EXP NAD results in increased expression of MUC2 mRNA CTD PMID:29935245 NCBI chr11:1,074,874...1,110,508
Ensembl chr11:1,074,875...1,110,511 		JBrowse link
G NADK NAD kinase increases phosphorylation EXP NADK protein results in increased phosphorylation of NAD CTD PMID:22954684 NCBI chr 1:1,751,232...1,780,514
Ensembl chr 1:1,751,232...1,780,457 		JBrowse link
G NADSYN1 NAD synthetase 1 multiple interactions EXP [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD CTD PMID:12547821 NCBI chr11:71,453,203...71,501,816
Ensembl chr11:71,453,109...71,524,107 		JBrowse link
G NAMPT nicotinamide phosphoribosyltransferase increases chemical synthesis
multiple interactions		 EXP
ISO		 NAMPT protein results in increased chemical synthesis of NAD
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased activity of NAMPT protein] which results in decreased abundance of NAD; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]		 CTD PMID:23834033 PMID:25505128 NCBI chr 7:106,248,298...106,285,888
Ensembl chr 7:106,248,298...106,285,966 		JBrowse link
G NDUFS4 NADH:ubiquinone oxidoreductase subunit S4 affects abundance ISO NDUFS4 protein affects the abundance of NAD CTD PMID:21383081 NCBI chr 5:53,560,639...53,683,338
Ensembl chr 5:53,560,633...53,683,338 		JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 increases oxidation
multiple interactions		 ISO NQO1 protein results in increased oxidation of NAD
NAD promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]		 CTD PMID:27558805 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668 		JBrowse link
G NR1H3 nuclear receptor subfamily 1 group H member 3 multiple interactions EXP [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein CTD PMID:27026705 NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033 		JBrowse link
G P2RY1 purinergic receptor P2Y1 multiple interactions EXP P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 3:152,835,131...152,841,439
Ensembl chr 3:152,835,131...152,841,439 		JBrowse link
G P2RY11 purinergic receptor P2Y11 multiple interactions EXP P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr19:10,111,693...10,115,372
Ensembl chr19:10,111,693...10,115,372 		JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 multiple interactions
decreases abundance
affects abundance		 ISO
EXP		 [Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD; benzamide inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; benzamide inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]
5-chloro-2-(3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl)-4(3H)-quinazolinone inhibits the reaction [PARP1 protein results in decreased abundance of NAD]
PARP1 protein mutant form affects the abundance of NAD
[2,5,2',5'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3,4,3',4'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]; Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; PARP1 protein promotes the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]
PARP1 protein affects the abundance of NAD		 CTD PMID:11593040 PMID:15075382 PMID:15147502 PMID:17669606 PMID:19433264 More... NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154 		JBrowse link
G PARP10 poly(ADP-ribose) polymerase family member 10 decreases abundance EXP PARP10 protein results in decreased abundance of NAD CTD PMID:33051211 NCBI chr 8:143,977,158...144,012,764
Ensembl chr 8:143,977,153...144,012,772 		JBrowse link
G PLA2G6 phospholipase A2 group VI multiple interactions EXP PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr22:38,111,495...38,181,830
Ensembl chr22:38,111,495...38,214,778 		JBrowse link
G PPARG peroxisome proliferator activated receptor gamma multiple interactions
decreases activity		 ISO 3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein] CTD PMID:18815186 NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356 		JBrowse link
G PPT1 palmitoyl-protein thioesterase 1 affects abundance ISO PPT1 gene mutant form affects the abundance of NAD CTD PMID:21224254 NCBI chr 1:40,071,461...40,097,252
Ensembl chr 1:40,072,710...40,097,260 		JBrowse link
G RDH10 retinol dehydrogenase 10 multiple interactions EXP NAD binds to and results in increased activity of RDH10 protein CTD PMID:25526675 NCBI chr 8:73,294,602...73,325,281
Ensembl chr 8:73,294,602...73,325,281 		JBrowse link
G RDH16 retinol dehydrogenase 16 multiple interactions EXP NAD binds to and results in increased activity of RDH16 protein CTD PMID:25526675 NCBI chr12:56,951,431...56,957,608
Ensembl chr12:56,951,431...56,959,374 		JBrowse link
G RDH5 retinol dehydrogenase 5 multiple interactions EXP NAD binds to and results in increased activity of RDH5 protein CTD PMID:25526675 NCBI chr12:55,720,393...55,724,705
Ensembl chr12:55,720,367...55,724,705 		JBrowse link
G SDR16C5 short chain dehydrogenase/reductase family 16C member 5 affects activity
multiple interactions		 EXP NAD affects the activity of SDR16C5 protein
NAD binds to and results in increased activity of SDR16C5 protein		 CTD PMID:18926804 PMID:25526675 NCBI chr 8:56,300,005...56,320,175
Ensembl chr 8:56,300,005...56,320,776 		JBrowse link
G SDR9C7 short chain dehydrogenase/reductase family 9C member 7 multiple interactions EXP NAD binds to and results in increased activity of SDR9C7 protein CTD PMID:25526675 NCBI chr12:56,923,133...56,934,408
Ensembl chr12:56,923,133...56,934,408 		JBrowse link
G SIRT1 sirtuin 1 multiple interactions
increases response to substance
increases activity
decreases abundance		 EXP
ISO		 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; [Resveratrol results in increased abundance of NAD] which results in increased expression of SIRT1 protein; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]
SIRT1 protein results in increased susceptibility to NAD
NAD results in increased activity of SIRT1 protein
[MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein
NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]		 CTD PMID:19288225 PMID:19928762 PMID:22561310 PMID:23834033 PMID:25536389 More... NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390 		JBrowse link
G SMPD2 sphingomyelin phosphodiesterase 2 affects activity EXP NAD affects the activity of SMPD2 protein CTD PMID:20518072 NCBI chr 6:109,440,724...109,443,919
Ensembl chr 6:109,440,724...109,443,919 		JBrowse link
G SPHK1 sphingosine kinase 1 decreases activity EXP NAD results in decreased activity of SPHK1 protein CTD PMID:20518072 NCBI chr17:76,383,204...76,387,855
Ensembl chr17:76,376,584...76,387,860 		JBrowse link
G TALDO1 transaldolase 1 decreases abundance ISO TALDO1 gene mutant form results in decreased abundance of NAD CTD PMID:19436114 NCBI chr11:747,464...765,012
Ensembl chr11:747,415...765,012 		JBrowse link
G TGDS TDP-glucose 4,6-dehydratase multiple interactions EXP NAD binds to and results in increased activity of TGDS protein CTD PMID:25526675 NCBI chr13:94,574,054...94,596,273
Ensembl chr13:94,574,054...94,596,242 		JBrowse link
G TP53 tumor protein p53 multiple interactions
decreases expression		 EXP
ISO		 [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]
NAD promotes the reaction [Acetaminophen results in decreased expression of TRP53 protein]
NAD results in decreased expression of TP53 protein		 CTD PMID:10334203 PMID:11461765 PMID:12390773 PMID:34216621 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538 		JBrowse link
G TYR tyrosinase multiple interactions
increases oxidation		 EXP ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD] CTD PMID:20685355 NCBI chr11:89,177,875...89,295,759
Ensembl chr11:89,177,875...89,295,759 		JBrowse link
G UXS1 UDP-glucuronate decarboxylase 1 multiple interactions EXP [thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 2:106,093,311...106,194,301
Ensembl chr 2:106,093,308...106,194,301 		JBrowse link
G XRCC1 X-ray repair cross complementing 1 decreases reduction
multiple interactions		 ISO
EXP		 XRCC1 gene mutant form results in decreased reduction of NAD
[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD; olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; XRCC1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]		 CTD PMID:30998386 PMID:35778544 NCBI chr19:43,543,311...43,575,527
Ensembl chr19:43,543,311...43,580,473 		JBrowse link
NAD(+) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACMSD aminocarboxymuconate semialdehyde decarboxylase increases abundance ISO ACMSD protein results in increased abundance of NAD CTD PMID:17896587 NCBI chr 2:134,838,616...134,902,034
Ensembl chr 2:134,838,616...134,902,034 		JBrowse link
G AKR1A1 aldo-keto reductase family 1 member A1 multiple interactions EXP NAD promotes the reaction [AKR1A1 protein affects the chemical synthesis of benzo(a)pyrene-7,8-dione]; NAD promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 NCBI chr 1:45,550,826...45,570,049
Ensembl chr 1:45,550,543...45,570,049 		JBrowse link
G AKR1C1 aldo-keto reductase family 1 member C1 multiple interactions EXP [AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr10:4,963,415...4,983,283
Ensembl chr10:4,963,253...4,983,283 		JBrowse link
G AKR1C2 aldo-keto reductase family 1 member C2 multiple interactions EXP [AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr10:4,987,775...5,018,000
Ensembl chr10:4,987,775...5,018,031 		JBrowse link
G AKR1C3 aldo-keto reductase family 1 member C3 multiple interactions EXP [AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr10:5,048,781...5,107,686
Ensembl chr10:5,035,354...5,107,686 		JBrowse link
G AKT1 AKT serine/threonine kinase 1 multiple interactions EXP 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein] CTD PMID:25536389 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751 		JBrowse link
G ALDH1A1 aldehyde dehydrogenase 1 family member A1 multiple interactions
increases activity		 EXP
ISO		 [ALDH1A1 protein binds to NAD] which results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; [NAD co-treated with propionaldehyde] inhibits the reaction [Acrolein results in decreased activity of ALDH1A1 protein]; ALDH1A1 protein binds to and results in increased reduction of NAD; NAD binds to and results in increased activity of ALDH1A1 protein; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH1A1 protein]
NAD results in increased activity of ALDH1A1 protein		 CTD PMID:10559215 PMID:10856427 PMID:21256123 PMID:22339434 PMID:25450233 NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442 		JBrowse link
G ALDH1B1 aldehyde dehydrogenase 1 family member B1 multiple interactions EXP [ALDH1B1 protein co-treated with NAD] results in increased metabolism of Acetaldehyde; [ALDH1B1 protein co-treated with NAD] results in increased metabolism of propionaldehyde CTD PMID:7779080 NCBI chr 9:38,392,702...38,398,661
Ensembl chr 9:38,392,702...38,398,661 		JBrowse link
G ALDH2 aldehyde dehydrogenase 2 family member multiple interactions
affects binding
affects abundance		 EXP
ISO		 [ALDH2 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; NAD inhibits the reaction [[Ethanol co-treated with Lead] results in decreased expression of and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Ethanol results in decreased expression of and results in decreased activity of ALDH2 protein]
ALDH2 protein binds to NAD
NAD binds to ALDH2 protein
Magnesium affects the reaction [NAD binds to ALDH2 protein]
ALDH2 gene polymorphism affects the abundance of NAD; ALDH2 protein affects the abundance of NAD		 CTD PMID:10559215 PMID:15629893 PMID:15900217 PMID:21276780 PMID:22339434 More... NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532 		JBrowse link
G ALDH3A1 aldehyde dehydrogenase 3 family member A1 multiple interactions
increases activity		 EXP
ISO		 [ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde
NAD results in increased activity of ALDH3A1 protein		 CTD PMID:10856427 PMID:21256123 NCBI chr17:19,737,984...19,748,298
Ensembl chr17:19,737,984...19,748,943 		JBrowse link
G ALDH5A1 aldehyde dehydrogenase 5 family member A1 multiple interactions ISO NAD binds to and affects the activity of ALDH5A1 protein CTD PMID:18926807 NCBI chr 6:24,494,969...24,537,207
Ensembl chr 6:24,494,867...24,537,207 		JBrowse link
G BAX BCL2 associated X, apoptosis regulator decreases expression EXP NAD results in decreased expression of BAX protein CTD PMID:12390773 NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798 		JBrowse link
G BCL2 BCL2 apoptosis regulator increases expression EXP NAD results in increased expression of BCL2 protein CTD PMID:12390773 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128 		JBrowse link
G BCL2L1 BCL2 like 1 multiple interactions ISO NAD inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] CTD PMID:11461765 NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989 		JBrowse link
G BDH1 3-hydroxybutyrate dehydrogenase 1 multiple interactions EXP NAD binds to and results in increased activity of BDH1 protein CTD PMID:25526675 NCBI chr 3:197,509,783...197,573,343
Ensembl chr 3:197,509,783...197,573,323 		JBrowse link
G BDH2 3-hydroxybutyrate dehydrogenase 2 multiple interactions EXP NAD binds to and results in increased activity of BDH2 protein CTD PMID:25526675 NCBI chr 4:103,077,592...103,099,834
Ensembl chr 4:103,077,592...103,099,870 		JBrowse link
G BMAL1 basic helix-loop-helix ARNT like 1 decreases oxidation ISO BMAL1 gene mutant form results in decreased oxidation of NAD CTD PMID:27056296 NCBI chr11:13,276,652...13,387,266
Ensembl chr11:13,276,652...13,387,266 		JBrowse link
G CASP3 caspase 3 multiple interactions ISO NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; NAD inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; NAD inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] CTD PMID:24040102 PMID:24491677 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062 		JBrowse link
G CAT catalase multiple interactions EXP CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] CTD PMID:10334203 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CBR4 carbonyl reductase 4 multiple interactions EXP NAD binds to and results in increased activity of CBR4 protein CTD PMID:25526675 NCBI chr 4:168,894,486...169,010,255
Ensembl chr 4:168,863,770...169,010,275 		JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A multiple interactions ISO NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] CTD PMID:22561310 NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337 		JBrowse link
G CDKN1B cyclin dependent kinase inhibitor 1B multiple interactions ISO NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] CTD PMID:22561310 NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369 		JBrowse link
G CHRNA9 cholinergic receptor nicotinic alpha 9 subunit multiple interactions EXP CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 4:40,335,333...40,355,217
Ensembl chr 4:40,335,333...40,355,217 		JBrowse link
G CSF2 colony stimulating factor 2 multiple interactions ISO [NAD results in increased abundance of Reactive Oxygen Species] which results in increased expression of CSF2 protein CTD PMID:11752025 NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170 		JBrowse link
G CYB5B cytochrome b5 type B multiple interactions EXP [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr16:69,424,619...69,466,264
Ensembl chr16:69,398,402...69,466,264 		JBrowse link
G CYB5R3 cytochrome b5 reductase 3 affects binding
multiple interactions		 EXP CYB5R3 protein binds to NAD
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine		 CTD PMID:16469290 PMID:25170804 NCBI chr22:42,617,840...42,649,392
Ensembl chr22:42,615,730...42,720,870 		JBrowse link
G DCXR dicarbonyl and L-xylulose reductase multiple interactions EXP 1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased reduction of Diacetyl; [DCXR protein co-treated with NAD] results in increased reduction of Xylulose; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin] CTD PMID:28595002 NCBI chr17:82,035,858...82,037,697
Ensembl chr17:82,035,136...82,037,709 		JBrowse link
G DEK DEK proto-oncogene increases oxidation EXP DEK protein results in increased oxidation of NAD CTD PMID:28558019 NCBI chr 6:18,223,860...18,264,530
Ensembl chr 6:18,223,860...18,264,548 		JBrowse link
G DHRS9 dehydrogenase/reductase 9 multiple interactions EXP NAD binds to and results in increased activity of DHRS9 protein CTD PMID:25526675 NCBI chr 2:169,067,077...169,096,167
Ensembl chr 2:169,064,789...169,096,167 		JBrowse link
G ENOX2 ecto-NOX disulfide-thiol exchanger 2 multiple interactions EXP [epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD; [phenoxodiol results in decreased activity of ENOX2 protein] which results in increased abundance of NAD CTD PMID:20518072 NCBI chr  X:130,622,325...130,903,209
Ensembl chr  X:130,622,325...130,903,234 		JBrowse link
G ERCC6 ERCC excision repair 6, chromatin remodeling factor multiple interactions
decreases abundance
increases ADP-ribosylation
increases metabolic processing		 EXP
ISO		 ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased abundance of NAD]; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]
nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD]
NAD results in increased ADP-ribosylation of ERCC6 protein
ERCC6 gene mutant form results in increased metabolism of NAD		 CTD PMID:25440059 NCBI chr10:49,434,881...49,539,538
Ensembl chr10:49,454,168...49,539,538 		JBrowse link
G GALE UDP-galactose-4-epimerase multiple interactions EXP NAD binds to and results in increased activity of GALE protein CTD PMID:25526675 NCBI chr 1:23,795,599...23,800,754
Ensembl chr 1:23,795,599...23,800,781 		JBrowse link
G GALNT1 polypeptide N-acetylgalactosaminyltransferase 1 increases expression EXP NAD results in increased expression of GALNT1 mRNA CTD PMID:29935245 NCBI chr18:35,580,922...35,711,834
Ensembl chr18:35,581,117...35,711,834 		JBrowse link
G GAPDH glyceraldehyde-3-phosphate dehydrogenase multiple interactions EXP
ISO		 [GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]		 CTD PMID:15788719 NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374 		JBrowse link
G GLB1 galactosidase beta 1 multiple interactions ISO NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] CTD PMID:22561310 NCBI chr 3:32,961,108...33,097,146
Ensembl chr 3:32,996,609...33,097,202 		JBrowse link
G GSK3B glycogen synthase kinase 3 beta increases abundance
multiple interactions		 EXP GSK3B protein mutant form results in increased abundance of NAD metabolite
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]		 CTD PMID:25246272 PMID:25536389 NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994 		JBrowse link
G GSR glutathione-disulfide reductase multiple interactions ISO NAD inhibits the reaction [Doxorubicin results in decreased activity of GSR protein] CTD PMID:24491677 NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846 		JBrowse link
G HADH hydroxyacyl-CoA dehydrogenase increases metabolic processing EXP HADH protein results in increased metabolism of NAD CTD PMID:10600649 NCBI chr 4:107,989,889...108,035,171
Ensembl chr 4:107,989,714...108,035,241 		JBrowse link
G HPGD 15-hydroxyprostaglandin dehydrogenase multiple interactions EXP [Celecoxib co-treated with NAD] binds to HPGD protein; [Diclofenac co-treated with NAD] binds to HPGD protein; [Dinoprostone co-treated with NAD] binds to HPGD protein; [Fenoprofen co-treated with NAD] binds to HPGD protein; [Indomethacin co-treated with NAD] binds to HPGD protein; [Ketoprofen co-treated with NAD] binds to HPGD protein; [Niflumic Acid co-treated with NAD] binds to HPGD protein; [pioglitazone co-treated with NAD] binds to HPGD protein; [rosiglitazone co-treated with NAD] binds to HPGD protein; NAD binds to and results in increased activity of HPGD protein CTD PMID:25526675 NCBI chr 4:174,490,175...174,522,893
Ensembl chr 4:174,490,175...174,523,154 		JBrowse link
G HPSE heparanase increases expression ISO NAD results in increased expression of HPSE mRNA; NAD results in increased expression of HPSE protein CTD PMID:19429930 NCBI chr 4:83,292,461...83,335,153
Ensembl chr 4:83,292,461...83,335,153 		JBrowse link
G HRAS HRas proto-oncogene, GTPase multiple interactions EXP [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene] CTD PMID:10334203 NCBI chr11:532,242...535,576
Ensembl chr11:532,242...537,321 		JBrowse link
G HSD11B1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions EXP [Androstane-3,17-diol co-treated with NAD] binds to HSD11B1 protein; [Disulfiram co-treated with NAD] binds to HSD11B1 protein; [Estradiol co-treated with NAD] binds to HSD11B1 protein; [Quercetin co-treated with NAD] binds to HSD11B1 protein; [Testosterone co-treated with NAD] binds to HSD11B1 protein CTD PMID:25526675 NCBI chr 1:209,686,179...209,734,929
Ensembl chr 1:209,686,178...209,734,949 		JBrowse link
G HSD11B2 hydroxysteroid 11-beta dehydrogenase 2 increases reduction
multiple interactions		 ISO
EXP		 HSD11B2 protein results in increased reduction of NAD
Ziram inhibits the reaction [HSD11B2 protein results in increased reduction of NAD]		 CTD PMID:26859423 NCBI chr16:67,429,801...67,437,553
Ensembl chr16:67,430,652...67,437,553 		JBrowse link
G HSD17B10 hydroxysteroid 17-beta dehydrogenase 10 multiple interactions EXP [20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein; [Androstane-3,17-diol co-treated with NAD] binds to HSD17B10 protein; [cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein; [Cholestanol co-treated with NAD] binds to HSD17B10 protein; [Pregnanolone co-treated with NAD] binds to HSD17B10 protein; [Progesterone co-treated with NAD] binds to HSD17B10 protein; NAD binds to and results in increased activity of HSD17B10 protein CTD PMID:25526675 NCBI chr  X:53,431,258...53,434,376
Ensembl chr  X:53,431,258...53,434,370 		JBrowse link
G HSD17B11 hydroxysteroid 17-beta dehydrogenase 11 multiple interactions EXP NAD binds to and results in increased activity of HSD17B11 protein CTD PMID:25526675 NCBI chr 4:87,336,515...87,391,188
Ensembl chr 4:87,336,515...87,391,188 		JBrowse link
G HSD17B13 hydroxysteroid 17-beta dehydrogenase 13 multiple interactions EXP NAD binds to and results in increased activity of HSD17B13 protein CTD PMID:25526675 NCBI chr 4:87,303,794...87,322,882
Ensembl chr 4:87,303,789...87,322,886 		JBrowse link
G HSD17B14 hydroxysteroid 17-beta dehydrogenase 14 multiple interactions EXP NAD binds to and results in increased activity of HSD17B14 protein CTD PMID:25526675 NCBI chr19:48,813,018...48,836,491
Ensembl chr19:48,813,018...48,836,510 		JBrowse link
G HSD17B2 hydroxysteroid 17-beta dehydrogenase 2 multiple interactions EXP NAD binds to and results in increased activity of HSD17B2 protein CTD PMID:25526675 NCBI chr16:82,035,253...82,098,534
Ensembl chr16:82,035,004...82,098,534 		JBrowse link
G HSD17B4 hydroxysteroid 17-beta dehydrogenase 4 multiple interactions EXP NAD binds to and results in increased activity of HSD17B4 protein CTD PMID:25526675 NCBI chr 5:119,452,497...119,542,332
Ensembl chr 5:119,452,465...119,637,199 		JBrowse link
G HSD17B6 hydroxysteroid 17-beta dehydrogenase 6 multiple interactions EXP NAD binds to and results in increased activity of HSD17B6 protein CTD PMID:25526675 NCBI chr12:56,763,324...56,787,790
Ensembl chr12:56,752,161...56,787,790 		JBrowse link
G HSD17B8 hydroxysteroid 17-beta dehydrogenase 8 multiple interactions EXP [Gossypol co-treated with NAD] binds to HSD17B8 protein CTD PMID:25526675 NCBI chr 6:33,204,655...33,206,831
Ensembl chr 6:33,204,655...33,206,831 		JBrowse link
G HSD3B1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions EXP NAD binds to and results in increased activity of HSD3B1 protein CTD PMID:25526675 NCBI chr 1:119,507,203...119,515,058
Ensembl chr 1:119,507,198...119,515,054 		JBrowse link
G HSD3B2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 multiple interactions EXP NAD binds to and results in increased activity of HSD3B2 protein CTD PMID:25526675 NCBI chr 1:119,414,931...119,423,034
Ensembl chr 1:119,414,931...119,423,035 		JBrowse link
G HSD3B7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions EXP NAD binds to and results in increased activity of HSD3B7 protein CTD PMID:25526675 NCBI chr16:30,985,207...30,989,147
Ensembl chr16:30,985,207...30,989,147 		JBrowse link
G IDH2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance		 ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD metabolite]; Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD]
IDH2 protein mutant form results in increased abundance of NAD; IDH2 protein mutant form results in increased abundance of NAD metabolite		 CTD PMID:27469509 NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,477 		JBrowse link
G IGFBP1 insulin like growth factor binding protein 1 multiple interactions
increases expression		 EXP NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]
NAD results in increased expression of IGFBP1 mRNA		 CTD PMID:32781018 NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660 		JBrowse link
G IL1B interleukin 1 beta multiple interactions EXP 2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G INSR insulin receptor multiple interactions EXP 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein] CTD PMID:25536389 NCBI chr19:7,112,265...7,294,414
Ensembl chr19:7,112,255...7,294,414 		JBrowse link
G LDHA lactate dehydrogenase A increases oxidation ISO LDHA protein results in increased oxidation of NAD CTD PMID:8632003 NCBI chr11:18,394,563...18,408,425
Ensembl chr11:18,394,560...18,408,425 		JBrowse link
G MIR34A microRNA 34a multiple interactions
decreases abundance		 ISO [[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD] CTD PMID:23834033 NCBI chr 1:9,151,668...9,151,777
Ensembl chr 1:9,151,668...9,151,777 		JBrowse link
G MTARC1 mitochondrial amidoxime reducing component 1 multiple interactions EXP [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine] CTD PMID:25170804 PMID:29856598 NCBI chr 1:220,786,913...220,819,659
Ensembl chr 1:220,786,352...220,819,659 		JBrowse link
G MTARC2 mitochondrial amidoxime reducing component 2 multiple interactions EXP [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr 1:220,748,322...220,784,815
Ensembl chr 1:220,748,225...220,784,815 		JBrowse link
G MUC2 mucin 2, oligomeric mucus/gel-forming increases expression EXP NAD results in increased expression of MUC2 mRNA CTD PMID:29935245 NCBI chr11:1,074,874...1,110,508
Ensembl chr11:1,074,875...1,110,511 		JBrowse link
G NADK NAD kinase increases phosphorylation EXP NADK protein results in increased phosphorylation of NAD CTD PMID:22954684 NCBI chr 1:1,751,232...1,780,514
Ensembl chr 1:1,751,232...1,780,457 		JBrowse link
G NADSYN1 NAD synthetase 1 multiple interactions EXP [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD CTD PMID:12547821 NCBI chr11:71,453,203...71,501,816
Ensembl chr11:71,453,109...71,524,107 		JBrowse link
G NAMPT nicotinamide phosphoribosyltransferase increases chemical synthesis
multiple interactions		 EXP
ISO		 NAMPT protein results in increased chemical synthesis of NAD
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased activity of NAMPT protein] which results in decreased abundance of NAD; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]		 CTD PMID:23834033 PMID:25505128 NCBI chr 7:106,248,298...106,285,888
Ensembl chr 7:106,248,298...106,285,966 		JBrowse link
G NDUFS4 NADH:ubiquinone oxidoreductase subunit S4 affects abundance ISO NDUFS4 protein affects the abundance of NAD CTD PMID:21383081 NCBI chr 5:53,560,639...53,683,338
Ensembl chr 5:53,560,633...53,683,338 		JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases oxidation		 ISO NAD promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]
NQO1 protein results in increased oxidation of NAD		 CTD PMID:27558805 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668 		JBrowse link
G NR1H3 nuclear receptor subfamily 1 group H member 3 multiple interactions EXP [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein CTD PMID:27026705 NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033 		JBrowse link
G P2RY1 purinergic receptor P2Y1 multiple interactions EXP P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 3:152,835,131...152,841,439
Ensembl chr 3:152,835,131...152,841,439 		JBrowse link
G P2RY11 purinergic receptor P2Y11 multiple interactions EXP P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr19:10,111,693...10,115,372
Ensembl chr19:10,111,693...10,115,372 		JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 multiple interactions
decreases abundance
affects abundance		 ISO
EXP		 [Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD; benzamide inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; benzamide inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]
5-chloro-2-(3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl)-4(3H)-quinazolinone inhibits the reaction [PARP1 protein results in decreased abundance of NAD]
PARP1 protein mutant form affects the abundance of NAD
[2,5,2',5'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3,4,3',4'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]; Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; PARP1 protein promotes the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]
PARP1 protein affects the abundance of NAD		 CTD PMID:11593040 PMID:15075382 PMID:15147502 PMID:17669606 PMID:19433264 More... NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154 		JBrowse link
G PARP10 poly(ADP-ribose) polymerase family member 10 decreases abundance EXP PARP10 protein results in decreased abundance of NAD CTD PMID:33051211 NCBI chr 8:143,977,158...144,012,764
Ensembl chr 8:143,977,153...144,012,772 		JBrowse link
G PLA2G6 phospholipase A2 group VI multiple interactions EXP PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr22:38,111,495...38,181,830
Ensembl chr22:38,111,495...38,214,778 		JBrowse link
G PPARG peroxisome proliferator activated receptor gamma multiple interactions
decreases activity		 ISO 3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein] CTD PMID:18815186 NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356 		JBrowse link
G PPT1 palmitoyl-protein thioesterase 1 affects abundance ISO PPT1 gene mutant form affects the abundance of NAD CTD PMID:21224254 NCBI chr 1:40,071,461...40,097,252
Ensembl chr 1:40,072,710...40,097,260 		JBrowse link
G RDH10 retinol dehydrogenase 10 multiple interactions EXP NAD binds to and results in increased activity of RDH10 protein CTD PMID:25526675 NCBI chr 8:73,294,602...73,325,281
Ensembl chr 8:73,294,602...73,325,281 		JBrowse link
G RDH16 retinol dehydrogenase 16 multiple interactions EXP NAD binds to and results in increased activity of RDH16 protein CTD PMID:25526675 NCBI chr12:56,951,431...56,957,608
Ensembl chr12:56,951,431...56,959,374 		JBrowse link
G RDH5 retinol dehydrogenase 5 multiple interactions EXP NAD binds to and results in increased activity of RDH5 protein CTD PMID:25526675 NCBI chr12:55,720,393...55,724,705
Ensembl chr12:55,720,367...55,724,705 		JBrowse link
G SDR16C5 short chain dehydrogenase/reductase family 16C member 5 affects activity
multiple interactions		 EXP NAD affects the activity of SDR16C5 protein
NAD binds to and results in increased activity of SDR16C5 protein		 CTD PMID:18926804 PMID:25526675 NCBI chr 8:56,300,005...56,320,175
Ensembl chr 8:56,300,005...56,320,776 		JBrowse link
G SDR9C7 short chain dehydrogenase/reductase family 9C member 7 multiple interactions EXP NAD binds to and results in increased activity of SDR9C7 protein CTD PMID:25526675 NCBI chr12:56,923,133...56,934,408
Ensembl chr12:56,923,133...56,934,408 		JBrowse link
G SIRT1 sirtuin 1 multiple interactions
increases response to substance
increases activity
decreases abundance		 EXP
ISO		 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; [Resveratrol results in increased abundance of NAD] which results in increased expression of SIRT1 protein; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]
SIRT1 protein results in increased susceptibility to NAD
NAD results in increased activity of SIRT1 protein
[MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein
NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]		 CTD PMID:19288225 PMID:19928762 PMID:22561310 PMID:23834033 PMID:25536389 More... NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390 		JBrowse link
G SMPD2 sphingomyelin phosphodiesterase 2 affects activity EXP NAD affects the activity of SMPD2 protein CTD PMID:20518072 NCBI chr 6:109,440,724...109,443,919
Ensembl chr 6:109,440,724...109,443,919 		JBrowse link
G SPHK1 sphingosine kinase 1 decreases activity EXP NAD results in decreased activity of SPHK1 protein CTD PMID:20518072 NCBI chr17:76,383,204...76,387,855
Ensembl chr17:76,376,584...76,387,860 		JBrowse link
G TALDO1 transaldolase 1 decreases abundance ISO TALDO1 gene mutant form results in decreased abundance of NAD CTD PMID:19436114 NCBI chr11:747,464...765,012
Ensembl chr11:747,415...765,012 		JBrowse link
G TGDS TDP-glucose 4,6-dehydratase multiple interactions EXP NAD binds to and results in increased activity of TGDS protein CTD PMID:25526675 NCBI chr13:94,574,054...94,596,273
Ensembl chr13:94,574,054...94,596,242 		JBrowse link
G TP53 tumor protein p53 multiple interactions
decreases expression		 EXP
ISO		 [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]
NAD promotes the reaction [Acetaminophen results in decreased expression of TRP53 protein]
NAD results in decreased expression of TP53 protein		 CTD PMID:10334203 PMID:11461765 PMID:12390773 PMID:34216621 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538 		JBrowse link
G TYR tyrosinase multiple interactions
increases oxidation		 EXP ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD] CTD PMID:20685355 NCBI chr11:89,177,875...89,295,759
Ensembl chr11:89,177,875...89,295,759 		JBrowse link
G UXS1 UDP-glucuronate decarboxylase 1 multiple interactions EXP [thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 2:106,093,311...106,194,301
Ensembl chr 2:106,093,308...106,194,301 		JBrowse link
G XRCC1 X-ray repair cross complementing 1 decreases reduction
multiple interactions		 ISO
EXP		 XRCC1 gene mutant form results in decreased reduction of NAD
[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD; olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; XRCC1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]		 CTD PMID:30998386 PMID:35778544 NCBI chr19:43,543,311...43,575,527
Ensembl chr19:43,543,311...43,580,473 		JBrowse link
NADP zwitterion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 multiple interactions EXP [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]] CTD PMID:35101544 NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324 		JBrowse link
G ACHE acetylcholinesterase (Yt blood group) multiple interactions ISO [Methyl Parathion co-treated with NADP] results in decreased activity of ACHE protein CTD PMID:11684353 NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974 		JBrowse link
G AIF1 allograft inflammatory factor 1 multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of AIF1 protein] CTD PMID:32057834 NCBI chr 6:31,615,234...31,617,015
Ensembl chr 6:31,615,217...31,617,021 		JBrowse link
G AKR1A1 aldo-keto reductase family 1 member A1 multiple interactions EXP [AKR1A1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1A1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:21910479 NCBI chr 1:45,550,826...45,570,049
Ensembl chr 1:45,550,543...45,570,049 		JBrowse link
G AKR1B1 aldo-keto reductase family 1 member B multiple interactions
increases activity
affects binding		 EXP [AKR1B1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B1 protein
NADP binds to AKR1B1 protein binds to fidarestat		 CTD PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 7:134,442,350...134,459,239
Ensembl chr 7:134,442,356...134,459,284 		JBrowse link
G AKR1B10 aldo-keto reductase family 1 member B10 multiple interactions
increases activity
affects binding
decreases reduction		 EXP [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde; [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B10 protein
NADP binds to AKR1B10 protein mutant form binds to fidarestat
AKR1B10 protein results in decreased reduction of NADP		 CTD PMID:17329238 PMID:19013440 PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 7:134,527,567...134,541,412
Ensembl chr 7:134,527,567...134,541,412 		JBrowse link
G AKR1C1 aldo-keto reductase family 1 member C1 multiple interactions EXP [AKR1C1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone] CTD PMID:21910479 PMID:23261716 NCBI chr10:4,963,415...4,983,283
Ensembl chr10:4,963,253...4,983,283 		JBrowse link
G AKR1C2 aldo-keto reductase family 1 member C2 multiple interactions EXP [AKR1C2 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP inhibits the reaction [AKR1C2 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr10:4,987,775...5,018,000
Ensembl chr10:4,987,775...5,018,031 		JBrowse link
G AKR1C3 aldo-keto reductase family 1 member C3 multiple interactions EXP [AKR1C3 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP inhibits the reaction [AKR1C3 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr10:5,048,781...5,107,686
Ensembl chr10:5,035,354...5,107,686 		JBrowse link
G AKR1C4 aldo-keto reductase family 1 member C4 multiple interactions EXP [AKR1C4 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C4 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP inhibits the reaction [AKR1C4 protein results in increased oxidation of Hydroxysteroids] CTD PMID:14672942 PMID:21910479 NCBI chr10:5,196,837...5,218,949
Ensembl chr10:5,195,462...5,218,949 		JBrowse link
G AKR1D1 aldo-keto reductase family 1 member D1 multiple interactions EXP [AKR1D1 protein co-treated with NADP] results in increased reduction of 7 alpha-hydroxy-4-cholesten-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Aldosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of cholest-4-en-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Corticosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Testosterone CTD PMID:25500266 NCBI chr 7:138,076,459...138,118,305
Ensembl chr 7:138,002,324...138,118,305 		JBrowse link
G AKR7A2 aldo-keto reductase family 7 member A2 multiple interactions EXP [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes CTD PMID:21910479 NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,303,965...19,312,144 		JBrowse link
G AKR7A3 aldo-keto reductase family 7 member A3 multiple interactions EXP [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione CTD PMID:21910479 NCBI chr 1:19,274,229...19,288,770
Ensembl chr 1:19,282,573...19,288,770 		JBrowse link
G ALDH2 aldehyde dehydrogenase 2 family member multiple interactions ISO 1-benzylimidazole inhibits the reaction [NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]]; NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein] CTD PMID:9585485 NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532 		JBrowse link
G ALDH3A1 aldehyde dehydrogenase 3 family member A1 multiple interactions
increases activity		 EXP
ISO		 [ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of benzaldehyde
NADP results in increased activity of ALDH3A1 protein		 CTD PMID:10856427 PMID:21256123 NCBI chr17:19,737,984...19,748,298
Ensembl chr17:19,737,984...19,748,943 		JBrowse link
G ATG5 autophagy related 5 multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of ATG5 protein] CTD PMID:32057834 NCBI chr 6:106,184,476...106,325,760
Ensembl chr 6:106,045,423...106,325,791 		JBrowse link
G BCHE butyrylcholinesterase multiple interactions EXP [diphenylcresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tert-butylphenyl diphenyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tri-o-cresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein] CTD PMID:23085349 NCBI chr 3:165,772,904...165,837,423
Ensembl chr 3:165,772,904...165,837,462 		JBrowse link
G BECN1 beclin 1 multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of BECN1 protein] CTD PMID:32057834 NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350 		JBrowse link
G CAT catalase multiple interactions ISO CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CBR1 carbonyl reductase 1 multiple interactions EXP [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [Genistein co-treated with NADP] binds to CBR1 protein; [Quercetin co-treated with NADP] binds to CBR1 protein; [Triclosan co-treated with NADP] binds to CBR1 protein; Curcumin inhibits the reaction [NADP metabolite binds to and results in increased activity of CBR1 protein]; NADP binds to and results in increased activity of CBR1 protein; NADP metabolite binds to and results in increased activity of CBR1 protein CTD PMID:21910479 PMID:25526675 PMID:25541467 NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166 		JBrowse link
G CBR3 carbonyl reductase 3 multiple interactions EXP NADP binds to and results in increased activity of CBR3 protein CTD PMID:25526675 NCBI chr21:36,135,079...36,146,562
Ensembl chr21:36,135,079...36,146,562 		JBrowse link
G CD38 CD38 molecule multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr 4:15,778,328...15,853,232
Ensembl chr 4:15,778,275...15,853,232 		JBrowse link
G CTSB cathepsin B multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of CTSB protein] CTD PMID:32057834 NCBI chr 8:11,842,524...11,868,087
Ensembl chr 8:11,842,524...11,869,533 		JBrowse link
G CTSD cathepsin D multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of CTSD protein] CTD PMID:32057834 NCBI chr11:1,752,755...1,763,927
Ensembl chr11:1,752,752...1,764,573 		JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 multiple interactions EXP [Benzo(a)pyrene co-treated with CXCL8 protein] results in decreased abundance of NADP CTD PMID:28238931 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716 		JBrowse link
G CYB5A cytochrome b5 type A multiple interactions EXP [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] CTD PMID:22390216 NCBI chr18:74,250,846...74,291,963
Ensembl chr18:74,250,846...74,291,973 		JBrowse link
G CYBB cytochrome b-245 beta chain multiple interactions ISO CYBB protein promotes the reaction [[Doxorubicin co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:17275678 NCBI chr  X:37,780,059...37,813,461
Ensembl chr  X:37,780,018...37,813,461 		JBrowse link
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 multiple interactions EXP
ISO		 NADP promotes the reaction [CYP1A1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP1A1 protein		 CTD PMID:15720144 PMID:24713513 NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536 		JBrowse link
G CYP1A2 cytochrome P450 family 1 subfamily A member 2 multiple interactions EXP [CYP1A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Resveratrol results in decreased activity of CYP1A2 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:7946932 PMID:11714871 PMID:20825217 PMID:24120545 PMID:33728909 NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607 		JBrowse link
G CYP1B1 cytochrome P450 family 1 subfamily B member 1 multiple interactions EXP [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,2',4,6'-tetramethoxystilbene; [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene; alpha-naphthoflavone inhibits the reaction [[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene]; NADP promotes the reaction [CYP1B1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]; NADP promotes the reaction [CYP1B1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:16120791 PMID:19463925 NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902 		JBrowse link
G CYP2A13 cytochrome P450 family 2 subfamily A member 13 multiple interactions EXP [NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene; [NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog; [NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog CTD PMID:27137136 NCBI chr19:41,088,451...41,096,195
Ensembl chr19:41,088,451...41,096,195 		JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 multiple interactions EXP [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of N'-nitrosonornicotine; [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B6 protein; [isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein; Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein] CTD PMID:11805216 PMID:16485904 PMID:25500267 PMID:32672941 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398 		JBrowse link
G CYP2C19 cytochrome P450 family 2 subfamily C member 19 multiple interactions EXP [2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein; [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ticlopidine inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:16978661 PMID:21177487 PMID:24120545 PMID:36332690 NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547 		JBrowse link
G CYP2C8 cytochrome P450 family 2 subfamily C member 8 multiple interactions EXP [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:24120545 NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497 		JBrowse link
G CYP2C9 cytochrome P450 family 2 subfamily C member 9 multiple interactions EXP [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C9 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C9 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C9 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C9 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C9 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [methysticin results in decreased activity of CYP2C9 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:16978661 PMID:24120545 PMID:35583123 NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091 		JBrowse link
G CYP2D6 cytochrome P450 family 2 subfamily D member 6 multiple interactions EXP [CYP2D6 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP deficiency inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:20825217 PMID:24120545 PMID:32198085 NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865 		JBrowse link
G CYP2E1 cytochrome P450 family 2 subfamily E member 1 multiple interactions EXP
ISO		 [vinyl carbamate co-treated with NADP] inhibits the reaction [CYP2E1 protein results in decreased methylation of Dimethylnitrosamine]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2E1 protein		 CTD PMID:11181492 PMID:24713513 NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220 		JBrowse link
G CYP2J2 cytochrome P450 family 2 subfamily J member 2 multiple interactions EXP NADP promotes the reaction [azelnidipine results in decreased activity of CYP2J2 protein]; NADP promotes the reaction [Felodipine results in decreased activity of CYP2J2 protein] CTD PMID:30965050 NCBI chr 1:59,893,308...59,969,212
Ensembl chr 1:59,893,308...59,926,773 		JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 multiple interactions EXP
ISO		 [2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [[CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone; [CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [NADP co-treated with CYP3A4 protein] results in increased activity of imidacloprid analog; [NADP co-treated with CYP3A4 protein] results in increased activity of Thiamethoxam; [retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; Dextromethorphan inhibits the reaction [[retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ketoconazole inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine]; Protons inhibits the reaction [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[CYP3A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine		 CTD PMID:16153789 PMID:19818743 PMID:20825217 PMID:21766881 PMID:22390216 More... NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248 		JBrowse link
G DCXR dicarbonyl and L-xylulose reductase multiple interactions EXP [2,6-dimethyl-1,4-benzoquinone co-treated with NADP] binds to DCXR protein; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [DCXR protein co-treated with NADP] results in increased reduction of Diacetyl; [DCXR protein co-treated with NADP] results in increased reduction of Xylulose; [Disulfiram co-treated with NADP] binds to DCXR protein; [Vitamin K 3 co-treated with NADP] binds to DCXR protein; Butyric Acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; Heptanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; hexanoic acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; NADP binds to and results in increased activity of DCXR protein; Pentanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl] CTD PMID:21910479 PMID:25526675 PMID:28595002 NCBI chr17:82,035,858...82,037,697
Ensembl chr17:82,035,136...82,037,709 		JBrowse link
G DECR1 2,4-dienoyl-CoA reductase 1 multiple interactions EXP NADP binds to and results in increased activity of DECR1 protein CTD PMID:25526675 NCBI chr 8:90,001,477...90,053,633
Ensembl chr 8:90,001,405...90,053,633 		JBrowse link
G DECR2 2,4-dienoyl-CoA reductase 2 multiple interactions EXP NADP binds to and results in increased activity of DECR2 protein CTD PMID:25526675 NCBI chr16:401,885...412,482
Ensembl chr16:401,858...412,487 		JBrowse link
G DHFR dihydrofolate reductase decreases activity EXP NADP analog results in decreased activity of DHFR protein CTD PMID:22954684 NCBI chr 5:80,626,226...80,654,983
Ensembl chr 5:80,626,226...80,654,983 		JBrowse link
G DHRS1 dehydrogenase/reductase 1 multiple interactions EXP NADP binds to and results in increased activity of DHRS1 protein CTD PMID:25526675 NCBI chr14:24,290,598...24,299,780
Ensembl chr14:24,290,598...24,299,780 		JBrowse link
G DHRS11 dehydrogenase/reductase 11 multiple interactions EXP NADP binds to and results in increased activity of DHRS11 protein CTD PMID:25526675 NCBI chr17:36,591,879...36,600,804
Ensembl chr17:36,591,879...36,600,804 		JBrowse link
G DHRS12 dehydrogenase/reductase 12 multiple interactions EXP NADP binds to and results in increased activity of DHRS12 protein CTD PMID:25526675 NCBI chr13:51,754,854...51,804,163
Ensembl chr13:51,767,993...51,804,163 		JBrowse link
G DHRS13 dehydrogenase/reductase 13 multiple interactions EXP NADP binds to and results in increased activity of DHRS13 protein CTD PMID:25526675 NCBI chr17:28,897,781...28,903,079
Ensembl chr17:28,897,781...28,903,079 		JBrowse link
G DHRS2 dehydrogenase/reductase 2 multiple interactions EXP [NADP co-treated with DHRS2 protein] affects the metabolism of 1-phenyl-1,2-propanedione; [NADP co-treated with DHRS2 protein] affects the metabolism of diethylglyoxime; [NADP co-treated with DHRS2 protein] affects the metabolism of Ketones; NADP binds to and results in increased activity of DHRS2 protein CTD PMID:16685466 PMID:25526675 NCBI chr14:23,630,115...23,645,639
Ensembl chr14:23,630,115...23,645,639 		JBrowse link
G DHRS3 dehydrogenase/reductase 3 multiple interactions
increases activity		 EXP NADP binds to and results in increased activity of DHRS3 protein
NADP results in increased activity of DHRS3 protein		 CTD PMID:25451588 PMID:25526675 NCBI chr 1:12,567,910...12,618,210
Ensembl chr 1:12,567,910...12,618,210 		JBrowse link
G DHRS4 dehydrogenase/reductase 4 multiple interactions EXP NADP binds to and results in increased activity of DHRS4 protein CTD PMID:25526675 NCBI chr14:23,953,770...23,969,279
Ensembl chr14:23,953,734...23,969,279 		JBrowse link
G DHRS7 dehydrogenase/reductase 7 multiple interactions EXP NADP binds to and results in increased activity of DHRS7 protein CTD PMID:25526675 NCBI chr14:60,144,119...60,169,889
Ensembl chr14:60,144,119...60,169,856 		JBrowse link
G DHRS7B dehydrogenase/reductase 7B multiple interactions EXP NADP binds to and results in increased activity of DHRS7B protein CTD PMID:25526675 NCBI chr17:21,126,964...21,191,420
Ensembl chr17:21,123,364...21,193,265 		JBrowse link
G DHRS7C dehydrogenase/reductase 7C multiple interactions EXP NADP binds to and results in increased activity of DHRS7C protein CTD PMID:25526675 NCBI chr17:9,771,438...9,791,592
Ensembl chr17:9,771,434...9,791,592 		JBrowse link
G FAR1 fatty acyl-CoA reductase 1 multiple interactions EXP NADP binds to and results in increased activity of FAR1 protein CTD PMID:25526675 NCBI chr11:13,668,668...13,732,346
Ensembl chr11:13,668,668...13,732,346 		JBrowse link
G FAR2 fatty acyl-CoA reductase 2 multiple interactions EXP NADP binds to and results in increased activity of FAR2 protein CTD PMID:25526675 NCBI chr12:29,149,278...29,335,616
Ensembl chr12:29,149,016...29,341,121 		JBrowse link
G FASLG Fas ligand multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876 		JBrowse link
G FASN fatty acid synthase multiple interactions EXP NADP binds to and results in increased activity of FASN protein CTD PMID:25526675 NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294 		JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 multiple interactions EXP
ISO		 [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-aminophenol; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoro-N-methylaniline metabolite; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoroaniline; [[FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline; Methimazole inhibits the reaction [[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol]		 CTD PMID:20369854 NCBI chr 1:171,248,494...171,285,978
Ensembl chr 1:171,248,471...171,285,978 		JBrowse link
G G6PD glucose-6-phosphate dehydrogenase increases reduction
increases expression		 EXP
ISO		 G6PD protein results in increased reduction of NADP
NADP results in increased expression of G6PD protein		 CTD PMID:1922005 PMID:5432368 NCBI chr  X:154,531,390...154,547,569
Ensembl chr  X:154,517,825...154,547,572 		JBrowse link
G GAPDH glyceraldehyde-3-phosphate dehydrogenase multiple interactions EXP NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] CTD PMID:15788719 NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374 		JBrowse link
G GFAP glial fibrillary acidic protein multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of GFAP protein] CTD PMID:32057834 NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937 		JBrowse link
G GFUS GDP-L-fucose synthase multiple interactions EXP NADP binds to and results in increased activity of GFUS protein CTD PMID:25526675 NCBI chr 8:143,612,618...143,618,048
Ensembl chr 8:143,612,618...143,618,048 		JBrowse link
G GLUD1 glutamate dehydrogenase 1 multiple interactions ISO [GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]; dipicolinic acid inhibits the reaction [[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]] CTD PMID:26639393 NCBI chr10:87,050,202...87,094,843
Ensembl chr10:87,050,202...87,094,843 		JBrowse link
G GMDS GDP-mannose 4,6-dehydratase multiple interactions EXP NADP binds to and results in increased activity of GMDS protein CTD PMID:25526675 NCBI chr 6:1,623,806...2,245,605
Ensembl chr 6:1,623,806...2,245,605 		JBrowse link
G GSK3B glycogen synthase kinase 3 beta increases abundance EXP GSK3B protein mutant form results in increased abundance of NADP metabolite CTD PMID:25246272 NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994 		JBrowse link
G GSR glutathione-disulfide reductase multiple interactions
increases oxidation		 EXP
ISO		 NADP affects the reaction [benzyl isothiocyanate results in decreased activity of GSR protein]; NADP affects the reaction [Carmustine results in decreased activity of GSR protein]
GSR protein results in increased oxidation of NADP
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]
Acetylcysteine inhibits the reaction [arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]]; arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]; Potassium Dichromate promotes the reaction [GSR protein results in increased oxidation of NADP]		 CTD PMID:17937621 PMID:19167472 PMID:19668867 PMID:22036979 PMID:24634002 NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846 		JBrowse link
G HSD11B1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions
increases reduction
increases oxidation		 EXP
ISO		 NADP binds to and results in increased activity of HSD11B1 protein
HSD11B1 protein results in increased reduction of NADP
Ziram inhibits the reaction [HSD11B1 protein results in increased oxidation of NADP]		 CTD PMID:25526675 PMID:26859423 NCBI chr 1:209,686,179...209,734,929
Ensembl chr 1:209,686,178...209,734,949 		JBrowse link
G HSD11B1L hydroxysteroid 11-beta dehydrogenase 1 like multiple interactions EXP NADP binds to and results in increased activity of HSD11B1L protein CTD PMID:25526675 NCBI chr19:5,681,027...5,688,522
Ensembl chr19:5,680,604...5,688,523 		JBrowse link
G HSD11B2 hydroxysteroid 11-beta dehydrogenase 2 multiple interactions EXP NADP binds to and results in increased activity of HSD11B2 protein CTD PMID:25526675 NCBI chr16:67,429,801...67,437,553
Ensembl chr16:67,430,652...67,437,553 		JBrowse link
G HSD17B1 hydroxysteroid 17-beta dehydrogenase 1 multiple interactions EXP [HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone; coumarin analog inhibits the reaction [[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone]; NADP binds to and results in increased activity of HSD17B1 protein CTD PMID:21232530 PMID:25526675 NCBI chr17:42,552,923...42,555,214
Ensembl chr17:42,552,922...42,555,214 		JBrowse link
G HSD17B12 hydroxysteroid 17-beta dehydrogenase 12 multiple interactions EXP NADP binds to and results in increased activity of HSD17B12 protein CTD PMID:25526675 NCBI chr11:43,556,721...43,856,615
Ensembl chr11:43,680,680...43,856,617 		JBrowse link
G HSD17B3 hydroxysteroid 17-beta dehydrogenase 3 multiple interactions ISO
EXP		 NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]; NADP binds to and results in increased activity of HSD17B3 protein		 CTD PMID:20522127 PMID:25526675 NCBI chr 9:96,235,306...96,302,176
Ensembl chr 9:96,235,306...96,302,176 		JBrowse link
G HSD17B7 hydroxysteroid 17-beta dehydrogenase 7 multiple interactions EXP NADP binds to and results in increased activity of HSD17B7 protein CTD PMID:25526675 NCBI chr 1:162,790,702...162,812,823
Ensembl chr 1:162,790,702...162,812,823 		JBrowse link
G HSD17B8 hydroxysteroid 17-beta dehydrogenase 8 multiple interactions EXP NADP binds to and results in increased activity of HSD17B8 protein CTD PMID:25526675 NCBI chr 6:33,204,655...33,206,831
Ensembl chr 6:33,204,655...33,206,831 		JBrowse link
G HSD3B1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions EXP [Carbenoxolone co-treated with NADP] binds to HSD3B1 protein; [Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein; [Vitamin K 3 co-treated with NADP] binds to HSD3B1 protein CTD PMID:25526675 NCBI chr 1:119,507,203...119,515,058
Ensembl chr 1:119,507,198...119,515,054 		JBrowse link
G HSDL1 hydroxysteroid dehydrogenase like 1 multiple interactions EXP NADP binds to and results in increased activity of HSDL1 protein CTD PMID:25526675 NCBI chr16:84,122,141...84,145,177
Ensembl chr16:84,122,141...84,145,192 		JBrowse link
G HSDL2 hydroxysteroid dehydrogenase like 2 multiple interactions EXP [22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein; [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; [Estradiol co-treated with NADP] binds to HSDL2 protein; [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; NADP binds to and results in increased activity of HSDL2 protein CTD PMID:25526675 NCBI chr 9:112,380,108...112,472,405
Ensembl chr 9:112,380,080...112,472,405 		JBrowse link
G HTATIP2 HIV-1 Tat interactive protein 2 multiple interactions EXP NADP binds to and results in increased activity of HTATIP2 protein CTD PMID:25526675 NCBI chr11:20,363,714...20,383,782
Ensembl chr11:20,363,685...20,383,782 		JBrowse link
G IDH2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance		 ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NADP] CTD PMID:27469509 NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,477 		JBrowse link
G INS-IGF2 INS-IGF2 readthrough multiple interactions ISO [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209 		JBrowse link
G IYD iodotyrosine deiodinase increases oxidation EXP IYD protein results in increased oxidation of NADP CTD PMID:33352258 NCBI chr 6:150,369,012...150,405,969
Ensembl chr 6:150,368,892...150,405,969 		JBrowse link
G KCNAB2 potassium voltage-gated channel subfamily A regulatory beta subunit 2 affects binding
multiple interactions		 ISO NADP binds to KCNAB2 protein
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxycyclopentenone)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxyisoprostane-E2)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-arachidonyl-3-phosphorylcholine metabolite		 CTD PMID:19013139 PMID:21296056 NCBI chr 1:5,992,676...6,101,180
Ensembl chr 1:5,990,927...6,101,193 		JBrowse link
G KDSR 3-ketodihydrosphingosine reductase multiple interactions EXP NADP binds to and results in increased activity of KDSR protein CTD PMID:25526675 NCBI chr18:63,327,726...63,367,206
Ensembl chr18:63,327,726...63,367,228 		JBrowse link
G KEAP1 kelch like ECH associated protein 1 affects abundance ISO KEAP1 protein affects the abundance of NADP CTD PMID:21775727 NCBI chr19:10,486,125...10,503,356
Ensembl chr19:10,486,125...10,503,558 		JBrowse link
G LAMP1 lysosomal associated membrane protein 1 multiple interactions ISO NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]] CTD PMID:33359019 NCBI chr13:113,297,239...113,323,672
Ensembl chr13:113,297,239...113,323,672 		JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:32057834 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779 		JBrowse link
G MAT2B methionine adenosyltransferase 2 non-catalytic beta subunit multiple interactions EXP [resveratrol co-treated with NADP] binds to MAT2B protein; NADP binds to and results in increased activity of MAT2B protein CTD PMID:25526675 NCBI chr 5:163,503,064...163,519,354
Ensembl chr 5:163,503,114...163,519,558 		JBrowse link
G NADK NAD kinase multiple interactions EXP [3-(1-deoxyribofuranosyl)benzamide results in decreased activity of NADK protein] which results in decreased abundance of NADP CTD PMID:22954684 NCBI chr 1:1,751,232...1,780,514
Ensembl chr 1:1,751,232...1,780,457 		JBrowse link
G NAT1 N-acetyltransferase 1 multiple interactions EXP [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr 8:18,170,467...18,223,689
Ensembl chr 8:18,170,477...18,223,689 		JBrowse link
G NAT2 N-acetyltransferase 2 multiple interactions EXP [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr 8:18,386,301...18,401,218
Ensembl chr 8:18,391,282...18,401,218 		JBrowse link
G NFE2L2 NFE2 like bZIP transcription factor 2 affects abundance
affects oxidation		 ISO NFE2L2 protein affects the abundance of NADP
NFE2L2 protein affects the oxidation of NADP		 CTD PMID:21775727 PMID:29950142 NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756 		JBrowse link
G NMRAL1 NmrA like redox sensor 1 multiple interactions EXP [Niflumic Acid co-treated with NADP] binds to NMRAL1 protein; [Triclosan co-treated with NADP] binds to NMRAL1 protein; NADP binds to and results in increased activity of NMRAL1 protein CTD PMID:25526675 NCBI chr16:4,461,694...4,476,337
Ensembl chr16:4,461,691...4,495,763 		JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP
ISO		 [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes
NADP promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]		 CTD PMID:20545351 PMID:21910479 PMID:27558805 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668 		JBrowse link
G NSDHL NAD(P) dependent steroid dehydrogenase-like multiple interactions EXP NADP binds to and results in increased activity of NSDHL protein CTD PMID:25526675 NCBI chr  X:152,831,063...152,869,729
Ensembl chr  X:152,830,967...152,869,729 		JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 multiple interactions EXP [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP] CTD PMID:17669606 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154 		JBrowse link
G PECR peroxisomal trans-2-enoyl-CoA reductase multiple interactions EXP [Acyl Coenzyme A co-treated with NADP] binds to PECR protein; [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein; NADP binds to and results in increased activity of PECR protein CTD PMID:25526675 NCBI chr 2:216,029,088...216,081,809
Ensembl chr 2:215,996,329...216,082,955 		JBrowse link
G PGD phosphogluconate dehydrogenase increases expression ISO NADP results in increased expression of PGD protein CTD PMID:1922005 NCBI chr 1:10,399,064...10,420,511
Ensembl chr 1:10,398,592...10,420,511 		JBrowse link
G POR cytochrome p450 oxidoreductase multiple interactions
increases metabolic processing		 ISO
EXP		 NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP promotes the reaction [POR protein results in increased reduction of Vitamin K 3]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP
diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP; [POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [POR protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [POR protein co-treated with NADP] results in increased chemical synthesis of Hydrogen Peroxide; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of Oxygen]; NADP promotes the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of Oxygen]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]		 CTD PMID:18206659 PMID:20545351 PMID:20561902 PMID:21215309 PMID:22390216 More... NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855 		JBrowse link
G PPIF peptidylprolyl isomerase F multiple interactions ISO [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein] CTD PMID:26975474 NCBI chr10:79,347,469...79,355,334
Ensembl chr10:79,347,469...79,355,334 		JBrowse link
G PRNP prion protein (Kanno blood group) multiple interactions ISO
EXP		 [NADP co-treated with cupric chloride] promotes the reaction [PRNP protein binds to PRNP protein]
[Copper co-treated with NADP] promotes the reaction [PRNP protein binds to PRNP protein]; [Copper co-treated with NADP] results in increased susceptibility to [PRNP protein binds to PRNP protein]		 CTD PMID:16990274 PMID:19149680 NCBI chr20:4,686,456...4,701,588
Ensembl chr20:4,686,350...4,701,590 		JBrowse link
G PTGR1 prostaglandin reductase 1 multiple interactions ISO [PTGR1 protein co-treated with NADP] affects the reduction of (2E)-decenal; [PTGR1 protein co-treated with NADP] affects the reduction of 1-pentene-3-one; [PTGR1 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-butenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-octenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-pentenal; [PTGR1 protein co-treated with NADP] affects the reduction of 3-buten-2-one; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of Acrolein; [PTGR1 protein co-treated with NADP] affects the reduction of benzylideneacetone; [PTGR1 protein co-treated with NADP] affects the reduction of Chalcone; [PTGR1 protein co-treated with NADP] affects the reduction of cinnamaldehyde; [PTGR1 protein co-treated with NADP] results in increased reduction of and results in increased activity of acylfulvene CTD PMID:11524419 PMID:21939268 NCBI chr 9:111,549,722...111,599,647
Ensembl chr 9:111,549,722...111,599,893 		JBrowse link
G QDPR quinoid dihydropteridine reductase multiple interactions EXP NADP binds to and results in increased activity of QDPR protein CTD PMID:25526675 NCBI chr 4:17,486,395...17,512,090
Ensembl chr 4:17,460,261...17,512,206 		JBrowse link
G RDH11 retinol dehydrogenase 11 multiple interactions EXP NADP binds to and results in increased activity of RDH11 protein CTD PMID:25526675 NCBI chr14:67,676,800...67,695,764
Ensembl chr14:67,676,800...67,695,793 		JBrowse link
G RDH12 retinol dehydrogenase 12 multiple interactions EXP NADP binds to and results in increased activity of RDH12 protein CTD PMID:25526675 NCBI chr14:67,701,886...67,734,451
Ensembl chr14:67,701,886...67,734,451 		JBrowse link
G RDH13 retinol dehydrogenase 13 multiple interactions EXP NADP binds to and results in increased activity of RDH13 protein CTD PMID:25526675 NCBI chr19:55,039,103...55,069,520
Ensembl chr19:55,039,108...55,071,291 		JBrowse link
G RDH14 retinol dehydrogenase 14 multiple interactions EXP NADP binds to and results in increased activity of RDH14 protein CTD PMID:25526675 NCBI chr 2:18,554,723...18,560,653
Ensembl chr 2:18,554,723...18,560,679 		JBrowse link
G RDH8 retinol dehydrogenase 8 multiple interactions EXP NADP binds to and results in increased activity of RDH8 protein CTD PMID:25526675 NCBI chr19:10,013,483...10,022,279
Ensembl chr19:10,013,249...10,022,279 		JBrowse link
G SDR39U1 short chain dehydrogenase/reductase family 39U member 1 multiple interactions EXP NADP binds to and results in increased activity of SDR39U1 protein CTD PMID:25526675 NCBI chr14:24,439,766...24,442,843
Ensembl chr14:24,439,766...24,442,905 		JBrowse link
G SDR42E1 short chain dehydrogenase/reductase family 42E, member 1 multiple interactions EXP NADP binds to and results in increased activity of SDR42E1 protein CTD PMID:25526675 NCBI chr16:81,988,855...82,011,470
Ensembl chr16:81,988,855...82,011,481 		JBrowse link
G SPR sepiapterin reductase multiple interactions EXP NADP binds to and results in increased activity of SPR protein CTD PMID:25526675 NCBI chr 2:72,887,408...72,892,158
Ensembl chr 2:72,887,382...72,892,158 		JBrowse link
G SQSTM1 sequestosome 1 multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in decreased expression of SQSTM1 protein] CTD PMID:32057834 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078 		JBrowse link
G SULT1A1 sulfotransferase family 1A member 1 multiple interactions EXP [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr16:28,605,258...28,623,375
Ensembl chr16:28,605,196...28,610,044 		JBrowse link
G TALDO1 transaldolase 1 decreases abundance
multiple interactions		 ISO TALDO1 gene mutant form results in decreased abundance of NADP
Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of NADP]		 CTD PMID:19436114 NCBI chr11:747,464...765,012
Ensembl chr11:747,415...765,012 		JBrowse link
G TDO2 tryptophan 2,3-dioxygenase affects abundance ISO TDO2 protein affects the abundance of NADP CTD PMID:7306070 NCBI chr 4:155,903,696...155,920,406
Ensembl chr 4:155,854,738...155,920,406 		JBrowse link
G TIGAR TP53 induced glycolysis regulatory phosphatase multiple interactions
increases abundance		 ISO NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein]
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]
TIGAR protein results in increased abundance of NADP		 CTD PMID:32057834 PMID:33359019 NCBI chr12:4,321,213...4,360,028
Ensembl chr12:4,307,763...4,360,028 		JBrowse link
G TP53 tumor protein p53 multiple interactions EXP NADP promotes the reaction [sodium bichromate results in increased expression of TP53 protein] CTD PMID:10942736 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538 		JBrowse link
G TXN thioredoxin multiple interactions ISO [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr 9:110,243,810...110,256,507
Ensembl chr 9:110,243,810...110,256,507 		JBrowse link
G TXNRD1 thioredoxin reductase 1 multiple interactions
increases reduction		 EXP
ISO		 [NADP co-treated with Mechlorethamine] results in decreased activity of TXNRD1 protein; NADP affects the reaction [benzyl isothiocyanate results in decreased activity of TXNRD1 protein]
NADP results in increased reduction of TXNRD1 protein
[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein; [NADP co-treated with Mechlorethamine] promotes the reaction [TXNRD1 protein binds to TXNRD1 protein]; [NADP co-treated with Mechlorethamine] results in decreased activity of and results in increased alkylation of TXNRD1 protein; [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; [Sodium Selenite co-treated with NADP] inhibits the reaction [Mercuric Chloride results in decreased activity of TXNRD1 protein]; [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; [TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]; Auranofin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dinitrochlorobenzene promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dithionitrobenzoic Acid inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; formic acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Glutathione inhibits the reaction [[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; NADP affects the reaction [arsenic trioxide results in decreased activity of TXNRD1 protein]; Oxygen deficiency inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Pentetic Acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Sodium Selenite inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]		 CTD PMID:17640917 PMID:17937621 PMID:20457604 PMID:20810785 PMID:22694104 More... NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307 		JBrowse link
G WWOX WW domain containing oxidoreductase multiple interactions EXP NADP binds to and results in increased activity of WWOX protein CTD PMID:25526675 NCBI chr16:78,099,654...79,212,667
Ensembl chr16:78,099,400...79,212,667 		JBrowse link
NADP(+) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 multiple interactions EXP [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]] CTD PMID:35101544 NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324 		JBrowse link
G ACHE acetylcholinesterase (Yt blood group) multiple interactions ISO [Methyl Parathion co-treated with NADP] results in decreased activity of ACHE protein CTD PMID:11684353 NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974 		JBrowse link
G AIF1 allograft inflammatory factor 1 multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of AIF1 protein] CTD PMID:32057834 NCBI chr 6:31,615,234...31,617,015
Ensembl chr 6:31,615,217...31,617,021 		JBrowse link
G AKR1A1 aldo-keto reductase family 1 member A1 multiple interactions EXP [AKR1A1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1A1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:21910479 NCBI chr 1:45,550,826...45,570,049
Ensembl chr 1:45,550,543...45,570,049 		JBrowse link
G AKR1B1 aldo-keto reductase family 1 member B multiple interactions
increases activity
affects binding		 EXP [AKR1B1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B1 protein
NADP binds to AKR1B1 protein binds to fidarestat		 CTD PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 7:134,442,350...134,459,239
Ensembl chr 7:134,442,356...134,459,284 		JBrowse link
G AKR1B10 aldo-keto reductase family 1 member B10 multiple interactions
increases activity
affects binding
decreases reduction		 EXP [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde; [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B10 protein
NADP binds to AKR1B10 protein mutant form binds to fidarestat
AKR1B10 protein results in decreased reduction of NADP		 CTD PMID:17329238 PMID:19013440 PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 7:134,527,567...134,541,412
Ensembl chr 7:134,527,567...134,541,412 		JBrowse link
G AKR1C1 aldo-keto reductase family 1 member C1 multiple interactions EXP [AKR1C1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone] CTD PMID:21910479 PMID:23261716 NCBI chr10:4,963,415...4,983,283
Ensembl chr10:4,963,253...4,983,283 		JBrowse link
G AKR1C2 aldo-keto reductase family 1 member C2 multiple interactions EXP [AKR1C2 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP inhibits the reaction [AKR1C2 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr10:4,987,775...5,018,000
Ensembl chr10:4,987,775...5,018,031 		JBrowse link
G AKR1C3 aldo-keto reductase family 1 member C3 multiple interactions EXP [AKR1C3 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP inhibits the reaction [AKR1C3 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr10:5,048,781...5,107,686
Ensembl chr10:5,035,354...5,107,686 		JBrowse link
G AKR1C4 aldo-keto reductase family 1 member C4 multiple interactions EXP [AKR1C4 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C4 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP inhibits the reaction [AKR1C4 protein results in increased oxidation of Hydroxysteroids] CTD PMID:14672942 PMID:21910479 NCBI chr10:5,196,837...5,218,949
Ensembl chr10:5,195,462...5,218,949 		JBrowse link
G AKR1D1 aldo-keto reductase family 1 member D1 multiple interactions EXP [AKR1D1 protein co-treated with NADP] results in increased reduction of 7 alpha-hydroxy-4-cholesten-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Aldosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of cholest-4-en-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Corticosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Testosterone CTD PMID:25500266 NCBI chr 7:138,076,459...138,118,305
Ensembl chr 7:138,002,324...138,118,305 		JBrowse link
G AKR7A2 aldo-keto reductase family 7 member A2 multiple interactions EXP [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes CTD PMID:21910479 NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,303,965...19,312,144 		JBrowse link
G AKR7A3 aldo-keto reductase family 7 member A3 multiple interactions EXP [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione CTD PMID:21910479 NCBI chr 1:19,274,229...19,288,770
Ensembl chr 1:19,282,573...19,288,770 		JBrowse link
G ALDH2 aldehyde dehydrogenase 2 family member multiple interactions ISO 1-benzylimidazole inhibits the reaction [NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]]; NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein] CTD PMID:9585485 NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532 		JBrowse link
G ALDH3A1 aldehyde dehydrogenase 3 family member A1 multiple interactions
increases activity		 EXP
ISO		 [ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of benzaldehyde
NADP results in increased activity of ALDH3A1 protein		 CTD PMID:10856427 PMID:21256123 NCBI chr17:19,737,984...19,748,298
Ensembl chr17:19,737,984...19,748,943 		JBrowse link
G ATG5 autophagy related 5 multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of ATG5 protein] CTD PMID:32057834 NCBI chr 6:106,184,476...106,325,760
Ensembl chr 6:106,045,423...106,325,791 		JBrowse link
G BCHE butyrylcholinesterase multiple interactions EXP [diphenylcresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tert-butylphenyl diphenyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tri-o-cresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein] CTD PMID:23085349 NCBI chr 3:165,772,904...165,837,423
Ensembl chr 3:165,772,904...165,837,462 		JBrowse link
G BECN1 beclin 1 multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of BECN1 protein] CTD PMID:32057834 NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350 		JBrowse link
G CAT catalase multiple interactions ISO CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CBR1 carbonyl reductase 1 multiple interactions EXP [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [Genistein co-treated with NADP] binds to CBR1 protein; [Quercetin co-treated with NADP] binds to CBR1 protein; [Triclosan co-treated with NADP] binds to CBR1 protein; Curcumin inhibits the reaction [NADP metabolite binds to and results in increased activity of CBR1 protein]; NADP binds to and results in increased activity of CBR1 protein; NADP metabolite binds to and results in increased activity of CBR1 protein CTD PMID:21910479 PMID:25526675 PMID:25541467 NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166 		JBrowse link
G CBR3 carbonyl reductase 3 multiple interactions EXP NADP binds to and results in increased activity of CBR3 protein CTD PMID:25526675 NCBI chr21:36,135,079...36,146,562
Ensembl chr21:36,135,079...36,146,562 		JBrowse link
G CD38 CD38 molecule multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr 4:15,778,328...15,853,232
Ensembl chr 4:15,778,275...15,853,232 		JBrowse link
G CTSB cathepsin B multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of CTSB protein] CTD PMID:32057834 NCBI chr 8:11,842,524...11,868,087
Ensembl chr 8:11,842,524...11,869,533 		JBrowse link
G CTSD cathepsin D multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of CTSD protein] CTD PMID:32057834 NCBI chr11:1,752,755...1,763,927
Ensembl chr11:1,752,752...1,764,573 		JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 multiple interactions EXP [Benzo(a)pyrene co-treated with CXCL8 protein] results in decreased abundance of NADP CTD PMID:28238931 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716 		JBrowse link
G CYB5A cytochrome b5 type A multiple interactions EXP [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] CTD PMID:22390216 NCBI chr18:74,250,846...74,291,963
Ensembl chr18:74,250,846...74,291,973 		JBrowse link
G CYBB cytochrome b-245 beta chain multiple interactions ISO CYBB protein promotes the reaction [[Doxorubicin co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:17275678 NCBI chr  X:37,780,059...37,813,461
Ensembl chr  X:37,780,018...37,813,461 		JBrowse link
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 multiple interactions EXP
ISO		 NADP promotes the reaction [CYP1A1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP1A1 protein		 CTD PMID:15720144 PMID:24713513 NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536 		JBrowse link
G CYP1A2 cytochrome P450 family 1 subfamily A member 2 multiple interactions EXP [CYP1A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Resveratrol results in decreased activity of CYP1A2 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:7946932 PMID:11714871 PMID:20825217 PMID:24120545 PMID:33728909 NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607 		JBrowse link
G CYP1B1 cytochrome P450 family 1 subfamily B member 1 multiple interactions EXP [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,2',4,6'-tetramethoxystilbene; [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene; alpha-naphthoflavone inhibits the reaction [[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene]; NADP promotes the reaction [CYP1B1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]; NADP promotes the reaction [CYP1B1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:16120791 PMID:19463925 NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902 		JBrowse link
G CYP2A13 cytochrome P450 family 2 subfamily A member 13 multiple interactions EXP [NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene; [NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog; [NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog CTD PMID:27137136 NCBI chr19:41,088,451...41,096,195
Ensembl chr19:41,088,451...41,096,195 		JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 multiple interactions EXP [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of N'-nitrosonornicotine; [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B6 protein; [isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein; Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein] CTD PMID:11805216 PMID:16485904 PMID:25500267 PMID:32672941 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398 		JBrowse link
G CYP2C19 cytochrome P450 family 2 subfamily C member 19 multiple interactions EXP [2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein; [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ticlopidine inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:16978661 PMID:21177487 PMID:24120545 PMID:36332690 NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547 		JBrowse link
G CYP2C8 cytochrome P450 family 2 subfamily C member 8 multiple interactions EXP [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:24120545 NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497 		JBrowse link
G CYP2C9 cytochrome P450 family 2 subfamily C member 9 multiple interactions EXP [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C9 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C9 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C9 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C9 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C9 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [methysticin results in decreased activity of CYP2C9 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:16978661 PMID:24120545 PMID:35583123 NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091 		JBrowse link
G CYP2D6 cytochrome P450 family 2 subfamily D member 6 multiple interactions EXP [CYP2D6 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP deficiency inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:20825217 PMID:24120545 PMID:32198085 NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865 		JBrowse link
G CYP2E1 cytochrome P450 family 2 subfamily E member 1 multiple interactions EXP
ISO		 [vinyl carbamate co-treated with NADP] inhibits the reaction [CYP2E1 protein results in decreased methylation of Dimethylnitrosamine]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2E1 protein		 CTD PMID:11181492 PMID:24713513 NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220 		JBrowse link
G CYP2J2 cytochrome P450 family 2 subfamily J member 2 multiple interactions EXP NADP promotes the reaction [azelnidipine results in decreased activity of CYP2J2 protein]; NADP promotes the reaction [Felodipine results in decreased activity of CYP2J2 protein] CTD PMID:30965050 NCBI chr 1:59,893,308...59,969,212
Ensembl chr 1:59,893,308...59,926,773 		JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 multiple interactions EXP
ISO		 [2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [[CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone; [CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [NADP co-treated with CYP3A4 protein] results in increased activity of imidacloprid analog; [NADP co-treated with CYP3A4 protein] results in increased activity of Thiamethoxam; [retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; Dextromethorphan inhibits the reaction [[retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ketoconazole inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine]; Protons inhibits the reaction [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[CYP3A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine		 CTD PMID:16153789 PMID:19818743 PMID:20825217 PMID:21766881 PMID:22390216 More... NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248 		JBrowse link
G DCXR dicarbonyl and L-xylulose reductase multiple interactions EXP [2,6-dimethyl-1,4-benzoquinone co-treated with NADP] binds to DCXR protein; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [DCXR protein co-treated with NADP] results in increased reduction of Diacetyl; [DCXR protein co-treated with NADP] results in increased reduction of Xylulose; [Disulfiram co-treated with NADP] binds to DCXR protein; [Vitamin K 3 co-treated with NADP] binds to DCXR protein; Butyric Acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; Heptanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; hexanoic acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; NADP binds to and results in increased activity of DCXR protein; Pentanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl] CTD PMID:21910479 PMID:25526675 PMID:28595002 NCBI chr17:82,035,858...82,037,697
Ensembl chr17:82,035,136...82,037,709 		JBrowse link
G DECR1 2,4-dienoyl-CoA reductase 1 multiple interactions EXP NADP binds to and results in increased activity of DECR1 protein CTD PMID:25526675 NCBI chr 8:90,001,477...90,053,633
Ensembl chr 8:90,001,405...90,053,633 		JBrowse link
G DECR2 2,4-dienoyl-CoA reductase 2 multiple interactions EXP NADP binds to and results in increased activity of DECR2 protein CTD PMID:25526675 NCBI chr16:401,885...412,482
Ensembl chr16:401,858...412,487 		JBrowse link
G DHFR dihydrofolate reductase decreases activity EXP NADP analog results in decreased activity of DHFR protein CTD PMID:22954684 NCBI chr 5:80,626,226...80,654,983
Ensembl chr 5:80,626,226...80,654,983 		JBrowse link
G DHRS1 dehydrogenase/reductase 1 multiple interactions EXP NADP binds to and results in increased activity of DHRS1 protein CTD PMID:25526675 NCBI chr14:24,290,598...24,299,780
Ensembl chr14:24,290,598...24,299,780 		JBrowse link
G DHRS11 dehydrogenase/reductase 11 multiple interactions EXP NADP binds to and results in increased activity of DHRS11 protein CTD PMID:25526675 NCBI chr17:36,591,879...36,600,804
Ensembl chr17:36,591,879...36,600,804 		JBrowse link
G DHRS12 dehydrogenase/reductase 12 multiple interactions EXP NADP binds to and results in increased activity of DHRS12 protein CTD PMID:25526675 NCBI chr13:51,754,854...51,804,163
Ensembl chr13:51,767,993...51,804,163 		JBrowse link
G DHRS13 dehydrogenase/reductase 13 multiple interactions EXP NADP binds to and results in increased activity of DHRS13 protein CTD PMID:25526675 NCBI chr17:28,897,781...28,903,079
Ensembl chr17:28,897,781...28,903,079 		JBrowse link
G DHRS2 dehydrogenase/reductase 2 multiple interactions EXP [NADP co-treated with DHRS2 protein] affects the metabolism of 1-phenyl-1,2-propanedione; [NADP co-treated with DHRS2 protein] affects the metabolism of diethylglyoxime; [NADP co-treated with DHRS2 protein] affects the metabolism of Ketones; NADP binds to and results in increased activity of DHRS2 protein CTD PMID:16685466 PMID:25526675 NCBI chr14:23,630,115...23,645,639
Ensembl chr14:23,630,115...23,645,639 		JBrowse link
G DHRS3 dehydrogenase/reductase 3 multiple interactions
increases activity		 EXP NADP binds to and results in increased activity of DHRS3 protein
NADP results in increased activity of DHRS3 protein		 CTD PMID:25451588 PMID:25526675 NCBI chr 1:12,567,910...12,618,210
Ensembl chr 1:12,567,910...12,618,210 		JBrowse link
G DHRS4 dehydrogenase/reductase 4 multiple interactions EXP NADP binds to and results in increased activity of DHRS4 protein CTD PMID:25526675 NCBI chr14:23,953,770...23,969,279
Ensembl chr14:23,953,734...23,969,279 		JBrowse link
G DHRS7 dehydrogenase/reductase 7 multiple interactions EXP NADP binds to and results in increased activity of DHRS7 protein CTD PMID:25526675 NCBI chr14:60,144,119...60,169,889
Ensembl chr14:60,144,119...60,169,856 		JBrowse link
G DHRS7B dehydrogenase/reductase 7B multiple interactions EXP NADP binds to and results in increased activity of DHRS7B protein CTD PMID:25526675 NCBI chr17:21,126,964...21,191,420
Ensembl chr17:21,123,364...21,193,265 		JBrowse link
G DHRS7C dehydrogenase/reductase 7C multiple interactions EXP NADP binds to and results in increased activity of DHRS7C protein CTD PMID:25526675 NCBI chr17:9,771,438...9,791,592
Ensembl chr17:9,771,434...9,791,592 		JBrowse link
G FAR1 fatty acyl-CoA reductase 1 multiple interactions EXP NADP binds to and results in increased activity of FAR1 protein CTD PMID:25526675 NCBI chr11:13,668,668...13,732,346
Ensembl chr11:13,668,668...13,732,346 		JBrowse link
G FAR2 fatty acyl-CoA reductase 2 multiple interactions EXP NADP binds to and results in increased activity of FAR2 protein CTD PMID:25526675 NCBI chr12:29,149,278...29,335,616
Ensembl chr12:29,149,016...29,341,121 		JBrowse link
G FASLG Fas ligand multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876 		JBrowse link
G FASN fatty acid synthase multiple interactions EXP NADP binds to and results in increased activity of FASN protein CTD PMID:25526675 NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294 		JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 multiple interactions EXP
ISO		 [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-aminophenol; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoro-N-methylaniline metabolite; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoroaniline; [[FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline; Methimazole inhibits the reaction [[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol]		 CTD PMID:20369854 NCBI chr 1:171,248,494...171,285,978
Ensembl chr 1:171,248,471...171,285,978 		JBrowse link
G G6PD glucose-6-phosphate dehydrogenase increases reduction
increases expression		 EXP
ISO		 G6PD protein results in increased reduction of NADP
NADP results in increased expression of G6PD protein		 CTD PMID:1922005 PMID:5432368 NCBI chr  X:154,531,390...154,547,569
Ensembl chr  X:154,517,825...154,547,572 		JBrowse link
G GAPDH glyceraldehyde-3-phosphate dehydrogenase multiple interactions EXP NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] CTD PMID:15788719 NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374 		JBrowse link
G GFAP glial fibrillary acidic protein multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of GFAP protein] CTD PMID:32057834 NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937 		JBrowse link
G GFUS GDP-L-fucose synthase multiple interactions EXP NADP binds to and results in increased activity of GFUS protein CTD PMID:25526675 NCBI chr 8:143,612,618...143,618,048
Ensembl chr 8:143,612,618...143,618,048 		JBrowse link
G GLUD1 glutamate dehydrogenase 1 multiple interactions ISO [GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]; dipicolinic acid inhibits the reaction [[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]] CTD PMID:26639393 NCBI chr10:87,050,202...87,094,843
Ensembl chr10:87,050,202...87,094,843 		JBrowse link
G GMDS GDP-mannose 4,6-dehydratase multiple interactions EXP NADP binds to and results in increased activity of GMDS protein CTD PMID:25526675 NCBI chr 6:1,623,806...2,245,605
Ensembl chr 6:1,623,806...2,245,605 		JBrowse link
G GSK3B glycogen synthase kinase 3 beta increases abundance EXP GSK3B protein mutant form results in increased abundance of NADP metabolite CTD PMID:25246272 NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994 		JBrowse link
G GSR glutathione-disulfide reductase multiple interactions
increases oxidation		 EXP
ISO		 NADP affects the reaction [benzyl isothiocyanate results in decreased activity of GSR protein]; NADP affects the reaction [Carmustine results in decreased activity of GSR protein]
GSR protein results in increased oxidation of NADP
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]
Acetylcysteine inhibits the reaction [arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]]; arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]; Potassium Dichromate promotes the reaction [GSR protein results in increased oxidation of NADP]		 CTD PMID:17937621 PMID:19167472 PMID:19668867 PMID:22036979 PMID:24634002 NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846 		JBrowse link
G HSD11B1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions
increases reduction
increases oxidation		 EXP
ISO		 NADP binds to and results in increased activity of HSD11B1 protein
HSD11B1 protein results in increased reduction of NADP
Ziram inhibits the reaction [HSD11B1 protein results in increased oxidation of NADP]		 CTD PMID:25526675 PMID:26859423 NCBI chr 1:209,686,179...209,734,929
Ensembl chr 1:209,686,178...209,734,949 		JBrowse link
G HSD11B1L hydroxysteroid 11-beta dehydrogenase 1 like multiple interactions EXP NADP binds to and results in increased activity of HSD11B1L protein CTD PMID:25526675 NCBI chr19:5,681,027...5,688,522
Ensembl chr19:5,680,604...5,688,523 		JBrowse link
G HSD11B2 hydroxysteroid 11-beta dehydrogenase 2 multiple interactions EXP NADP binds to and results in increased activity of HSD11B2 protein CTD PMID:25526675 NCBI chr16:67,429,801...67,437,553
Ensembl chr16:67,430,652...67,437,553 		JBrowse link
G HSD17B1 hydroxysteroid 17-beta dehydrogenase 1 multiple interactions EXP [HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone; coumarin analog inhibits the reaction [[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone]; NADP binds to and results in increased activity of HSD17B1 protein CTD PMID:21232530 PMID:25526675 NCBI chr17:42,552,923...42,555,214
Ensembl chr17:42,552,922...42,555,214 		JBrowse link
G HSD17B12 hydroxysteroid 17-beta dehydrogenase 12 multiple interactions EXP NADP binds to and results in increased activity of HSD17B12 protein CTD PMID:25526675 NCBI chr11:43,556,721...43,856,615
Ensembl chr11:43,680,680...43,856,617 		JBrowse link
G HSD17B3 hydroxysteroid 17-beta dehydrogenase 3 multiple interactions ISO
EXP		 NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]; NADP binds to and results in increased activity of HSD17B3 protein		 CTD PMID:20522127 PMID:25526675 NCBI chr 9:96,235,306...96,302,176
Ensembl chr 9:96,235,306...96,302,176 		JBrowse link
G HSD17B7 hydroxysteroid 17-beta dehydrogenase 7 multiple interactions EXP NADP binds to and results in increased activity of HSD17B7 protein CTD PMID:25526675 NCBI chr 1:162,790,702...162,812,823
Ensembl chr 1:162,790,702...162,812,823 		JBrowse link
G HSD17B8 hydroxysteroid 17-beta dehydrogenase 8 multiple interactions EXP NADP binds to and results in increased activity of HSD17B8 protein CTD PMID:25526675 NCBI chr 6:33,204,655...33,206,831
Ensembl chr 6:33,204,655...33,206,831 		JBrowse link
G HSD3B1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions EXP [Carbenoxolone co-treated with NADP] binds to HSD3B1 protein; [Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein; [Vitamin K 3 co-treated with NADP] binds to HSD3B1 protein CTD PMID:25526675 NCBI chr 1:119,507,203...119,515,058
Ensembl chr 1:119,507,198...119,515,054 		JBrowse link
G HSDL1 hydroxysteroid dehydrogenase like 1 multiple interactions EXP NADP binds to and results in increased activity of HSDL1 protein CTD PMID:25526675 NCBI chr16:84,122,141...84,145,177
Ensembl chr16:84,122,141...84,145,192 		JBrowse link
G HSDL2 hydroxysteroid dehydrogenase like 2 multiple interactions EXP [22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein; [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; [Estradiol co-treated with NADP] binds to HSDL2 protein; [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; NADP binds to and results in increased activity of HSDL2 protein CTD PMID:25526675 NCBI chr 9:112,380,108...112,472,405
Ensembl chr 9:112,380,080...112,472,405 		JBrowse link
G HTATIP2 HIV-1 Tat interactive protein 2 multiple interactions EXP NADP binds to and results in increased activity of HTATIP2 protein CTD PMID:25526675 NCBI chr11:20,363,714...20,383,782
Ensembl chr11:20,363,685...20,383,782 		JBrowse link
G IDH2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance		 ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NADP] CTD PMID:27469509 NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,477 		JBrowse link
G INS-IGF2 INS-IGF2 readthrough multiple interactions ISO [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209 		JBrowse link
G IYD iodotyrosine deiodinase increases oxidation EXP IYD protein results in increased oxidation of NADP CTD PMID:33352258 NCBI chr 6:150,369,012...150,405,969
Ensembl chr 6:150,368,892...150,405,969 		JBrowse link
G KCNAB2 potassium voltage-gated channel subfamily A regulatory beta subunit 2 affects binding
multiple interactions		 ISO NADP binds to KCNAB2 protein
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxycyclopentenone)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxyisoprostane-E2)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-arachidonyl-3-phosphorylcholine metabolite		 CTD PMID:19013139 PMID:21296056 NCBI chr 1:5,992,676...6,101,180
Ensembl chr 1:5,990,927...6,101,193 		JBrowse link
G KDSR 3-ketodihydrosphingosine reductase multiple interactions EXP NADP binds to and results in increased activity of KDSR protein CTD PMID:25526675 NCBI chr18:63,327,726...63,367,206
Ensembl chr18:63,327,726...63,367,228 		JBrowse link
G KEAP1 kelch like ECH associated protein 1 affects abundance ISO KEAP1 protein affects the abundance of NADP CTD PMID:21775727 NCBI chr19:10,486,125...10,503,356
Ensembl chr19:10,486,125...10,503,558 		JBrowse link
G LAMP1 lysosomal associated membrane protein 1 multiple interactions ISO NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]] CTD PMID:33359019 NCBI chr13:113,297,239...113,323,672
Ensembl chr13:113,297,239...113,323,672 		JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:32057834 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779 		JBrowse link
G MAT2B methionine adenosyltransferase 2 non-catalytic beta subunit multiple interactions EXP [resveratrol co-treated with NADP] binds to MAT2B protein; NADP binds to and results in increased activity of MAT2B protein CTD PMID:25526675 NCBI chr 5:163,503,064...163,519,354
Ensembl chr 5:163,503,114...163,519,558 		JBrowse link
G NADK NAD kinase multiple interactions EXP [3-(1-deoxyribofuranosyl)benzamide results in decreased activity of NADK protein] which results in decreased abundance of NADP CTD PMID:22954684 NCBI chr 1:1,751,232...1,780,514
Ensembl chr 1:1,751,232...1,780,457 		JBrowse link
G NAT1 N-acetyltransferase 1 multiple interactions EXP [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr 8:18,170,467...18,223,689
Ensembl chr 8:18,170,477...18,223,689 		JBrowse link
G NAT2 N-acetyltransferase 2 multiple interactions EXP [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr 8:18,386,301...18,401,218
Ensembl chr 8:18,391,282...18,401,218 		JBrowse link
G NFE2L2 NFE2 like bZIP transcription factor 2 affects abundance
affects oxidation		 ISO NFE2L2 protein affects the abundance of NADP
NFE2L2 protein affects the oxidation of NADP		 CTD PMID:21775727 PMID:29950142 NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756 		JBrowse link
G NMRAL1 NmrA like redox sensor 1 multiple interactions EXP [Niflumic Acid co-treated with NADP] binds to NMRAL1 protein; [Triclosan co-treated with NADP] binds to NMRAL1 protein; NADP binds to and results in increased activity of NMRAL1 protein CTD PMID:25526675 NCBI chr16:4,461,694...4,476,337
Ensembl chr16:4,461,691...4,495,763 		JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP
ISO		 [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes
NADP promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]		 CTD PMID:20545351 PMID:21910479 PMID:27558805 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668 		JBrowse link
G NSDHL NAD(P) dependent steroid dehydrogenase-like multiple interactions EXP NADP binds to and results in increased activity of NSDHL protein CTD PMID:25526675 NCBI chr  X:152,831,063...152,869,729
Ensembl chr  X:152,830,967...152,869,729 		JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 multiple interactions EXP [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP] CTD PMID:17669606 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154 		JBrowse link
G PECR peroxisomal trans-2-enoyl-CoA reductase multiple interactions EXP [Acyl Coenzyme A co-treated with NADP] binds to PECR protein; [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein; NADP binds to and results in increased activity of PECR protein CTD PMID:25526675 NCBI chr 2:216,029,088...216,081,809
Ensembl chr 2:215,996,329...216,082,955 		JBrowse link
G PGD phosphogluconate dehydrogenase increases expression ISO NADP results in increased expression of PGD protein CTD PMID:1922005 NCBI chr 1:10,399,064...10,420,511
Ensembl chr 1:10,398,592...10,420,511 		JBrowse link
G POR cytochrome p450 oxidoreductase multiple interactions
increases metabolic processing		 ISO
EXP		 NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP promotes the reaction [POR protein results in increased reduction of Vitamin K 3]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP
diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP; [POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [POR protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [POR protein co-treated with NADP] results in increased chemical synthesis of Hydrogen Peroxide; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of Oxygen]; NADP promotes the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of Oxygen]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]		 CTD PMID:18206659 PMID:20545351 PMID:20561902 PMID:21215309 PMID:22390216 More... NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855 		JBrowse link
G PPIF peptidylprolyl isomerase F multiple interactions ISO [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein] CTD PMID:26975474 NCBI chr10:79,347,469...79,355,334
Ensembl chr10:79,347,469...79,355,334 		JBrowse link
G PRNP prion protein (Kanno blood group) multiple interactions ISO
EXP		 [NADP co-treated with cupric chloride] promotes the reaction [PRNP protein binds to PRNP protein]
[Copper co-treated with NADP] promotes the reaction [PRNP protein binds to PRNP protein]; [Copper co-treated with NADP] results in increased susceptibility to [PRNP protein binds to PRNP protein]		 CTD PMID:16990274 PMID:19149680 NCBI chr20:4,686,456...4,701,588
Ensembl chr20:4,686,350...4,701,590 		JBrowse link
G PTGR1 prostaglandin reductase 1 multiple interactions ISO [PTGR1 protein co-treated with NADP] affects the reduction of (2E)-decenal; [PTGR1 protein co-treated with NADP] affects the reduction of 1-pentene-3-one; [PTGR1 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-butenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-octenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-pentenal; [PTGR1 protein co-treated with NADP] affects the reduction of 3-buten-2-one; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of Acrolein; [PTGR1 protein co-treated with NADP] affects the reduction of benzylideneacetone; [PTGR1 protein co-treated with NADP] affects the reduction of Chalcone; [PTGR1 protein co-treated with NADP] affects the reduction of cinnamaldehyde; [PTGR1 protein co-treated with NADP] results in increased reduction of and results in increased activity of acylfulvene CTD PMID:11524419 PMID:21939268 NCBI chr 9:111,549,722...111,599,647
Ensembl chr 9:111,549,722...111,599,893 		JBrowse link
G QDPR quinoid dihydropteridine reductase multiple interactions EXP NADP binds to and results in increased activity of QDPR protein CTD PMID:25526675 NCBI chr 4:17,486,395...17,512,090
Ensembl chr 4:17,460,261...17,512,206 		JBrowse link
G RDH11 retinol dehydrogenase 11 multiple interactions EXP NADP binds to and results in increased activity of RDH11 protein CTD PMID:25526675 NCBI chr14:67,676,800...67,695,764
Ensembl chr14:67,676,800...67,695,793 		JBrowse link
G RDH12 retinol dehydrogenase 12 multiple interactions EXP NADP binds to and results in increased activity of RDH12 protein CTD PMID:25526675 NCBI chr14:67,701,886...67,734,451
Ensembl chr14:67,701,886...67,734,451 		JBrowse link
G RDH13 retinol dehydrogenase 13 multiple interactions EXP NADP binds to and results in increased activity of RDH13 protein CTD PMID:25526675 NCBI chr19:55,039,103...55,069,520
Ensembl chr19:55,039,108...55,071,291 		JBrowse link
G RDH14 retinol dehydrogenase 14 multiple interactions EXP NADP binds to and results in increased activity of RDH14 protein CTD PMID:25526675 NCBI chr 2:18,554,723...18,560,653
Ensembl chr 2:18,554,723...18,560,679 		JBrowse link
G RDH8 retinol dehydrogenase 8 multiple interactions EXP NADP binds to and results in increased activity of RDH8 protein CTD PMID:25526675 NCBI chr19:10,013,483...10,022,279
Ensembl chr19:10,013,249...10,022,279 		JBrowse link
G SDR39U1 short chain dehydrogenase/reductase family 39U member 1 multiple interactions EXP NADP binds to and results in increased activity of SDR39U1 protein CTD PMID:25526675 NCBI chr14:24,439,766...24,442,843
Ensembl chr14:24,439,766...24,442,905 		JBrowse link
G SDR42E1 short chain dehydrogenase/reductase family 42E, member 1 multiple interactions EXP NADP binds to and results in increased activity of SDR42E1 protein CTD PMID:25526675 NCBI chr16:81,988,855...82,011,470
Ensembl chr16:81,988,855...82,011,481 		JBrowse link
G SPR sepiapterin reductase multiple interactions EXP NADP binds to and results in increased activity of SPR protein CTD PMID:25526675 NCBI chr 2:72,887,408...72,892,158
Ensembl chr 2:72,887,382...72,892,158 		JBrowse link
G SQSTM1 sequestosome 1 multiple interactions ISO NADP inhibits the reaction [Kainic Acid results in decreased expression of SQSTM1 protein] CTD PMID:32057834 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078 		JBrowse link
G SULT1A1 sulfotransferase family 1A member 1 multiple interactions EXP [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr16:28,605,258...28,623,375
Ensembl chr16:28,605,196...28,610,044 		JBrowse link
G TALDO1 transaldolase 1 decreases abundance
multiple interactions		 ISO TALDO1 gene mutant form results in decreased abundance of NADP
Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of NADP]		 CTD PMID:19436114 NCBI chr11:747,464...765,012
Ensembl chr11:747,415...765,012 		JBrowse link
G TDO2 tryptophan 2,3-dioxygenase affects abundance ISO TDO2 protein affects the abundance of NADP CTD PMID:7306070 NCBI chr 4:155,903,696...155,920,406
Ensembl chr 4:155,854,738...155,920,406 		JBrowse link
G TIGAR TP53 induced glycolysis regulatory phosphatase multiple interactions
increases abundance		 ISO NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein]
TIGAR protein results in increased abundance of NADP
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]		 CTD PMID:32057834 PMID:33359019 NCBI chr12:4,321,213...4,360,028
Ensembl chr12:4,307,763...4,360,028 		JBrowse link
G TP53 tumor protein p53 multiple interactions EXP NADP promotes the reaction [sodium bichromate results in increased expression of TP53 protein] CTD PMID:10942736 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538 		JBrowse link
G TXN thioredoxin multiple interactions ISO [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr 9:110,243,810...110,256,507
Ensembl chr 9:110,243,810...110,256,507 		JBrowse link
G TXNRD1 thioredoxin reductase 1 multiple interactions
increases reduction		 EXP
ISO		 [NADP co-treated with Mechlorethamine] results in decreased activity of TXNRD1 protein; NADP affects the reaction [benzyl isothiocyanate results in decreased activity of TXNRD1 protein]
NADP results in increased reduction of TXNRD1 protein
[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein; [NADP co-treated with Mechlorethamine] promotes the reaction [TXNRD1 protein binds to TXNRD1 protein]; [NADP co-treated with Mechlorethamine] results in decreased activity of and results in increased alkylation of TXNRD1 protein; [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; [Sodium Selenite co-treated with NADP] inhibits the reaction [Mercuric Chloride results in decreased activity of TXNRD1 protein]; [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; [TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]; Auranofin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dinitrochlorobenzene promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dithionitrobenzoic Acid inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; formic acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Glutathione inhibits the reaction [[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; NADP affects the reaction [arsenic trioxide results in decreased activity of TXNRD1 protein]; Oxygen deficiency inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Pentetic Acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Sodium Selenite inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]		 CTD PMID:17640917 PMID:17937621 PMID:20457604 PMID:20810785 PMID:22694104 More... NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307 		JBrowse link
G WWOX WW domain containing oxidoreductase multiple interactions EXP NADP binds to and results in increased activity of WWOX protein CTD PMID:25526675 NCBI chr16:78,099,654...79,212,667
Ensembl chr16:78,099,400...79,212,667 		JBrowse link
nicotinic acid-adenine dinucleotide phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CD38 CD38 molecule multiple interactions ISO CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr 4:15,778,328...15,853,232
Ensembl chr 4:15,778,275...15,853,232 		JBrowse link
G EDN1 endothelin 1 increases metabolic processing
multiple interactions		 ISO EDN1 protein results in increased metabolism of NAADP
NOX1 mutant form inhibits the reaction [EDN1 protein results in increased metabolism of NAADP]		 CTD PMID:23940720 NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194 		JBrowse link
G FASLG Fas ligand multiple interactions
increases abundance		 ISO CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876 		JBrowse link
G MCOLN1 mucolipin TRP cation channel 1 increases activity
multiple interactions		 EXP NAADP results in increased activity of MCOLN1 protein
[NAADP results in increased activity of MCOLN1 protein] which affects the localization of Calcium		 CTD PMID:21613607 NCBI chr19:7,522,624...7,534,009
Ensembl chr19:7,522,624...7,534,009 		JBrowse link
G NOX1 NADPH oxidase 1 multiple interactions ISO NOX1 mutant form inhibits the reaction [EDN1 protein results in increased metabolism of NAADP] CTD PMID:23940720 NCBI chr  X:100,843,324...100,874,359
Ensembl chr  X:100,843,324...100,874,359 		JBrowse link
NMN zwitterion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACADM acyl-CoA dehydrogenase medium chain multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of ACADM mRNA] CTD PMID:23834033 NCBI chr 1:75,724,709...75,763,679
Ensembl chr 1:75,724,431...75,787,575 		JBrowse link
G ACP5 acid phosphatase 5, tartrate resistant multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of ACP5 protein] CTD PMID:30292833 NCBI chr19:11,574,660...11,578,975
Ensembl chr19:11,574,653...11,579,993 		JBrowse link
G AXIN1 axin 1 multiple interactions EXP Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in increased expression of AXIN1 protein] CTD PMID:32005247 NCBI chr16:287,440...352,723
Ensembl chr16:287,440...352,723 		JBrowse link
G BGLAP bone gamma-carboxyglutamate protein multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in decreased expression of BGLAP protein]
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in decreased activity of BGLAP protein]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in decreased expression of BGLAP protein]		 CTD PMID:30292833 NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317 		JBrowse link
G CASP1 caspase 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of CASP1 protein modified form] CTD PMID:30292833 NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250 		JBrowse link
G CCND1 cyclin D1 multiple interactions EXP Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CCND1 protein]; Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased expression of CCND1 protein] CTD PMID:32005247 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474 		JBrowse link
G CTNNB1 catenin beta 1 multiple interactions EXP Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CTNNB1 protein]; Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased expression of CTNNB1 protein] CTD PMID:32005247 NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096 		JBrowse link
G ERCC6 ERCC excision repair 6, chromatin remodeling factor decreases abundance EXP ERCC6 gene mutant form results in decreased abundance of Nicotinamide Mononucleotide CTD PMID:25440059 NCBI chr10:49,434,881...49,539,538
Ensembl chr10:49,454,168...49,539,538 		JBrowse link
G FOXO4 forkhead box O4 multiple interactions EXP Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of FOXO4 mRNA] CTD PMID:36336710 NCBI chr  X:71,095,851...71,103,532
Ensembl chr  X:71,095,851...71,103,532 		JBrowse link
G GALNT1 polypeptide N-acetylgalactosaminyltransferase 1 increases expression EXP Nicotinamide Mononucleotide results in increased expression of GALNT1 mRNA CTD PMID:29935245 NCBI chr18:35,580,922...35,711,834
Ensembl chr18:35,581,117...35,711,834 		JBrowse link
G GLB1 galactosidase beta 1 multiple interactions ISO [resveratrol co-treated with Nicotinamide Mononucleotide] inhibits the reaction [RETN protein results in increased activity of GLB1 protein] CTD PMID:23827175 NCBI chr 3:32,961,108...33,097,146
Ensembl chr 3:32,996,609...33,097,202 		JBrowse link
G H2AX H2A.X variant histone multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of H2AX protein] CTD PMID:36756972 NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465 		JBrowse link
G IL18 interleukin 18 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of IL18 protein] CTD PMID:30292833 NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,253...112,164,096 		JBrowse link
G IL1B interleukin 1 beta multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of IL1B protein] CTD PMID:30292833 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G MIR34A microRNA 34a multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of ACADM mRNA]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARA mRNA]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARD mRNA] CTD PMID:23834033 NCBI chr 1:9,151,668...9,151,777
Ensembl chr 1:9,151,668...9,151,777 		JBrowse link
G NAMPT nicotinamide phosphoribosyltransferase affects binding
multiple interactions		 ISO
EXP		 NAMPT protein binds to Nicotinamide Mononucleotide
Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CCND1 protein]; Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CTNNB1 protein]
Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]		 CTD PMID:16901503 PMID:23834033 PMID:32005247 NCBI chr 7:106,248,298...106,285,888
Ensembl chr 7:106,248,298...106,285,966 		JBrowse link
G NLRP3 NLR family pyrin domain containing 3 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 protein]
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 protein]		 CTD PMID:30292833 NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,416,156...247,449,108 		JBrowse link
G NNT nicotinamide nucleotide transhydrogenase multiple interactions EXP 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein]]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of FOXO4 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of PPARGC1A mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of SHANK2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein] CTD PMID:36336710 NCBI chr 5:43,602,675...43,707,396
Ensembl chr 5:43,602,692...43,707,405 		JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 affects abundance
multiple interactions		 EXP
ISO		 PARP1 protein affects the abundance of Nicotinamide Mononucleotide
[Nicotinamide Mononucleotide co-treated with Cisplatin] results in decreased expression of PARP1 protein		 CTD PMID:19426698 PMID:34089817 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154 		JBrowse link
G PPARA peroxisome proliferator activated receptor alpha multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARA mRNA] CTD PMID:23834033 NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755 		JBrowse link
G PPARD peroxisome proliferator activated receptor delta multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARD mRNA] CTD PMID:23834033 NCBI chr 6:35,342,558...35,428,178
Ensembl chr 6:35,342,558...35,428,191 		JBrowse link
G PPARGC1A PPARG coactivator 1 alpha multiple interactions EXP Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of PPARGC1A mRNA] CTD PMID:36336710 NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089 		JBrowse link
G PYCARD PYD and CARD domain containing multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of PYCARD protein] CTD PMID:30292833 NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450 		JBrowse link
G RETN resistin multiple interactions ISO [resveratrol co-treated with Nicotinamide Mononucleotide] inhibits the reaction [RETN protein results in increased activity of GLB1 protein] CTD PMID:23827175 NCBI chr19:7,669,049...7,670,455
Ensembl chr19:7,669,049...7,670,455 		JBrowse link
G SHANK2 SH3 and multiple ankyrin repeat domains 2 multiple interactions EXP Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of SHANK2 mRNA] CTD PMID:36336710 NCBI chr11:70,467,854...71,253,228
Ensembl chr11:70,467,854...71,252,577 		JBrowse link
G SIRT1 sirtuin 1 increases expression
multiple interactions		 ISO Nicotinamide Mononucleotide results in increased expression of SIRT1 mRNA
Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in decreased expression of SIRT1 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in decreased expression of SIRT1 protein]		 CTD PMID:32087266 NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390 		JBrowse link
G SLC47A1 solute carrier family 47 member 1 multiple interactions EXP Nicotinamide Mononucleotide inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:22419765 NCBI chr17:19,533,854...19,579,034
Ensembl chr17:19,495,385...19,579,034 		JBrowse link
G SLC47A2 solute carrier family 47 member 2 multiple interactions EXP Nicotinamide Mononucleotide inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:22419765 NCBI chr17:19,678,317...19,718,979
Ensembl chr17:19,678,288...19,718,979 		JBrowse link
G SQSTM1 sequestosome 1 multiple interactions EXP 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein]]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein] CTD PMID:36336710 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078 		JBrowse link
G TXNIP thioredoxin interacting protein multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP protein] CTD PMID:30292833 NCBI chr 1:145,992,435...145,996,579
Ensembl chr 1:145,992,435...145,996,579 		JBrowse link
G UCP2 uncoupling protein 2 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in increased expression of UCP2 protein] CTD PMID:32087266 NCBI chr11:73,974,672...73,983,202
Ensembl chr11:73,974,672...73,982,843 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 26041
    chemical entity 26020
      atom 26016
        nonmetal atom 25505
          nitrogen atom 22541
            nitrogen molecular entity 22541
              organonitrogen compound 21934
                organonitrogen heterocyclic compound 20345
                  pyridines 12194
                    pyridine nucleotide 213
                      1-(5-O-phosphono-beta-D-ribofuranosyl)-5-(sulfanylcarbonyl)pyridinium-3-carbonyl adenylate 0
                      1-(5-O-phosphono-beta-D-ribofuranosyl)pyridin-4(1H)-one 0
                      5-carboxy-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium-3-carbonyl adenylate 0
                      Ni(II)-pyridinium-3,5-bisthiocarboxylic acid mononucleotide 0
                      nicotinamide nucleotide + 213
                      nicotinic acid nucleotide + 95
                      pyridinium-3,5-biscarboxylic acid mononucleotide + 0
                      pyridinium-3,5-bisthiocarboxylic acid mononucleotide 0
                      pyridinium-3-carboxy-5-thiocarboxylic acid mononucleotide 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 26041
    subatomic particle 26016
      composite particle 26016
        hadron 26016
          baryon 26016
            nucleon 26016
              atomic nucleus 26016
                atom 26016
                  main group element atom 25841
                    p-block element atom 25841
                      chalcogen 24924
                        oxygen atom 24814
                          oxygen molecular entity 24814
                            hydroxides 24056
                              oxoacid 22984
                                pnictogen oxoacid 13805
                                  phosphorus oxoacid 12864
                                    phosphoric acids 11885
                                      phosphoric acid 11885
                                        phosphoric acid derivative 11686
                                          phosphate 11685
                                            organic phosphate 11685
                                              nucleoside phosphate 1890
                                                nucleotide 1887
                                                  pyridine nucleotide 213
                                                    1-(5-O-phosphono-beta-D-ribofuranosyl)-5-(sulfanylcarbonyl)pyridinium-3-carbonyl adenylate 0
                                                    1-(5-O-phosphono-beta-D-ribofuranosyl)pyridin-4(1H)-one 0
                                                    5-carboxy-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium-3-carbonyl adenylate 0
                                                    Ni(II)-pyridinium-3,5-bisthiocarboxylic acid mononucleotide 0
                                                    nicotinamide nucleotide + 213
                                                    nicotinic acid nucleotide + 95
                                                    pyridinium-3,5-biscarboxylic acid mononucleotide + 0
                                                    pyridinium-3,5-bisthiocarboxylic acid mononucleotide 0
                                                    pyridinium-3-carboxy-5-thiocarboxylic acid mononucleotide 0
paths to the root